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Genetic associations at 53 loci highlight cell types
and biological pathways relevant for kidney
function
Cristian Pattaro et al.#
Reduced glomerular ﬁltration rate deﬁnes chronic kidney disease and is associated with
cardiovascular and all-cause mortality. We conducted a meta-analysis of genome-wide
association studies for estimated glomerular ﬁltration rate (eGFR), combining data across
133,413 individuals with replication in up to 42,166 individuals. We identify 24 new and
conﬁrm 29 previously identiﬁed loci. Of these 53 loci, 19 associate with eGFR among indi-
viduals with diabetes. Using bioinformatics, we show that identiﬁed genes at eGFR loci are
enriched for expression in kidney tissues and in pathways relevant for kidney development
and transmembrane transporter activity, kidney structure, and regulation of glucose
metabolism. Chromatin state mapping and DNase I hypersensitivity analyses across adult
tissues demonstrate preferential mapping of associated variants to regulatory regions in
kidney but not extra-renal tissues. These ﬁndings suggest that genetic determinants of eGFR
are mediated largely through direct effects within the kidney and highlight important cell
types and biological pathways.
Correspondence and requests for materials should be addressed to C.P. (email: cristian.pattaro@eurac.edu) or to A.K. (email: anna.koettgen@uniklinik-freiburg.de)
or to C.S.F. (email: foxca@nhlbi.nih.gov).
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C
hronic kidney disease (CKD) is a global public health
problem1–3, and is associated with an increased risk for
cardiovascular disease, all-cause mortality and end-stage
renal disease4,5. Few new therapies have been developed to prevent
or treat CKD over the past two decades1,6, underscoring the need to
identify and understand the underlying mechanisms of CKD.
Prior genome-wide association studies (GWAS) have identiﬁed
multiple genetic loci associated with CKD and estimated
glomerular ﬁltration rate (eGFR), a measure of the kidney’s
ﬁltration ability that is used to diagnose and stage CKD7–15.
Subsequent functional investigations point towards clinically
relevant novel mechanisms in CKD that were derived from initial
GWAS ﬁndings16, providing proof of principle that locus
discovery through large-scale GWAS efforts can translate to
new insights into CKD pathogenesis.
To identify additional genetic variants associated with eGFR
and guide future experimental studies of CKD-related mechan-
isms, we have now performed GWAS meta-analyses in up to
133,413 individuals, more than double the sample size of previous
studies. Here we describe multiple novel genomic loci associated
with kidney function traits and provide extensive locus
characterization and bioinformatics analyses, further delineating
the physiologic basis of kidney function.
Results
Stage 1 discovery analysis. We analysed associations of eGFR
based on serum creatinine (eGFRcrea), cystatin C (eGFRcys, an
additional, complementary biomarker of renal function) and
CKD (deﬁned as eGFRcrea o60mlmin 1 per 1.73m2) with
B2.5 million autosomal single-nucleotide polymorphisms (SNPs)
in up to 133,413 individuals of European ancestry from 49 pre-
dominantly population-based studies (Supplementary Table 1).
Results from discovery GWAS meta-analysis are publicly avail-
able at http://fox.nhlbi.nih.gov/CKDGen/. We performed ana-
lyses in each study sample in the overall population and stratiﬁed
by diabetes status, since genetic susceptibility to CKD may differ
in the presence of this strong clinical CKD risk factor. Population
stratiﬁcation did not impact our results as evidenced by low
genomic inﬂation factors in our meta-analyses, which ranged
from 1.00 to 1.04 across all our analyses (Supplementary Fig. 1).
In addition to conﬁrming 29 previously identiﬁed loci7–9
(Fig. 1a; Supplementary Table 2), we identiﬁed 48 independent
novel loci (Supplementary Table 3) where the index SNP, deﬁned
as the variant with the lowest P value in the region, had an
association P value o1.0 10 6. Of these 48 novel SNPs, 21
were genome-wide signiﬁcant with P values o5.0 10 8.
Overall, 43 SNPs were identiﬁed in association with eGFRcrea
(nine in the non-diabetes sample), one with eGFRcys and four
with CKD, as reported in Supplementary Table 3. Manhattan
plots for CKD, eGFRcys and eGFRcrea in diabetes are shown in
Fig. 1b,c and Supplementary Fig. 2, respectively.
Stage-2 replication. Novel loci were tested for replication in up to
42,166 additional European ancestry individuals from 15 studies
(Supplementary Table 1). Of the 48 novel candidate SNPs sub-
mitted to replication, 24 SNPs demonstrated a genome-wide
signiﬁcant combined stage 1 and 2 P value o5.0 10 8
(Table 1). Of these, 23 fulﬁlled additional replication criteria
(q-value o0.05 in stage 2). Only rs6795744 at the WNT7A locus
demonstrated suggestive replication (P value o5.0 10 8,
q-value 40.05). Because serum creatinine is used to estimate
eGFRcrea, associated genetic loci may be relevant to creatinine
production or metabolism rather than kidney function per se.
For this reason, we contrasted associations of eGFRcrea
versus eGFRcys, the latter estimated from an alternative and
creatinine-independent biomarker of GFR (Supplementary Fig. 3;
Supplementary Table 4). The majority of loci (22/24)
demonstrated consistent effect directions of their association with
both eGFRcrea and eGFRcys.
Association plots of the 24 newly identiﬁed genomic regions
that contain a replicated or suggestive index SNP appear in
Supplementary Fig. 4. The odds ratio for CKD for each of the
novel loci ranged from 0.93 to 1.06 (Supplementary Table 4). As
evidenced by the relatively small effect sizes, the proportion of
phenotypic variance of eGFRcrea explained by all new and known
loci was 3.22%: 0.81% for the newly uncovered loci and 2.41% for
the already known loci.
Associations stratiﬁed by diabetes and hypertension status. The
effects of the 53 known and novel loci in individuals with
(stage 1þ stage 2 n¼ 16,477) and without (stage 1þ stage 2
n¼ 154,881) diabetes were highly correlated (correlation coefﬁ-
cient: 0.80; 95% conﬁdence interval: 0.67, 0.88; Supplementary
Fig. 5) and of similar magnitude (Fig. 2; Supplementary Table 5),
suggesting that identiﬁcation of genetic loci in the overall popu-
lation may also provide insights into loci with potential impor-
tance among individuals with diabetes. The previously identiﬁed
UMOD locus showed genome-wide signiﬁcant association with
eGFRcrea among those with diabetes (Supplementary Fig. 2;
rs12917707, P value¼ 2.5 10 8), and six loci (NFKB1, UNCX,
TSPAN9, AP5B1, SIPA1L3 and PTPRO) had nominally signiﬁcant
associations with eGFRcrea among those with diabetes. Of the
previously identiﬁed loci, 13 demonstrated nominal associations
among those with diabetes, for a total of 19 loci associated with
eGFRcrea in diabetes.
Exploratory comparison of the association effect sizes in
subjects with and without hypertension based on our previous
work7 showed that novel and known loci are also similarly
associated with eGFRcrea among individuals with and without
hypertension (Supplementary Fig. 6).
Tests for SNP associations with related phenotypes. We tested
for overlap with traits that are known to be associated with kidney
function in the epidemiologic literature by investigating SNP
associations with systolic and diastolic blood pressure17, myocardial
infarction18, left ventricular mass19, heart failure20, fasting
glucose21 and urinary albumin excretion (CKDGen Consortium,
personal communication). We observed little association of the 24
novel SNPs with other kidney function-related traits, with only 2
out of 165 tests reaching the Bonferroni signiﬁcance level of 0.0003
(see Methods and Supplementary Table 6).
To investigate whether additional traits are associated with the
24 new eGFR loci, we queried the NHGRI GWAS catalog
(www.genome.gov). Overall, nine loci were previously identiﬁed
in association with other traits at a P value of 5.0 10 8 or lower
(Supplementary Table 7), including body mass index (ETV5) and
serum urate (INHBC, A1CF and AP5B1).
Trans-ethnic analyses. To assess the generalizability of our
ﬁndings across ethnicities, we evaluated the association of the
24 newly identiﬁed loci with eGFRcrea in 16,840 participants of
12 African ancestry population studies (Supplementary Table 8)
and in up to 42,296 Asians from the AGEN consortium11
(Supplementary Table 9). Seven SNPs achieved nominal
direction-consistent signiﬁcance (Po0.05) in AGEN, and one
SNP was signiﬁcant in the African ancestry meta-analysis
(Supplementary Table 9). Random-effect meta-analysis showed
that 12 loci (SDCCAG8, LRP2, IGFBP5, SKIL, UNCX, KBTBD2,
A1CF, KCNQ1, AP5B1, PTPRO, TP53INP2 and BCAS1) had fully
consistent effect direction across the three ethnic groups
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Figure 1 | Discovery stage genome-wide association analysis. Manhattan plots for eGFRcrea, CKD and eGFRcys. Previously reported loci are highlighted
in light blue (grey labels). (a) Novel loci uncovered for eGFRcrea in the overall and in the non-diabetes groups are highlighted in blue and green,
respectively. (b) Results from CKD analysis with highlighted known and novel loci for eGFRcrea. (c) Results from eGFRcys with highlighted known and novel
loci for eGFRcrea and known eGFRcys loci.
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(Supplementary Fig. 7), suggesting that our ﬁndings can likely be
generalized beyond the European ancestry group.
To identify additional potentially associated variants and more
formally evaluate trans-ethnic heterogeneity of the loci identiﬁed
through meta-analysis in European ancestry populations, we
performed a trans-ethnic meta-analysis22, combining the 12
African ancestry studies with the 48 European Ancestry studies
used in the discovery analysis of eGFRcrea. Of the 24 new loci
uncovered for eGFRcrea, 15 were also genome-wide signiﬁcant in
the trans-ethnic meta-analysis (deﬁned as log10 Bayes Factor46,
Supplementary Table 10), indicating that for most of these loci,
there is little to no allelic effect heterogeneity across the two
ethnic groups. No additional loci were signiﬁcantly associated
with log10 Bayes Factor 46.
Bioinformatic and functional characterization of new loci. We
used several techniques to prioritize and characterize genes
underlying the identiﬁed associations, uncover connections between
associated regions, detect relevant tissues and assign functional
annotations to associated variants. These included expression
quantitative trait loci (eQTL) analyses, pathway analyses, DNAse I
hypersensitivity site (DHS) mapping, chromatin mapping, manual
curation of genes in each region and zebraﬁsh knockdown.
eQTL analysis. We performed eQTL analysis using publically
available eQTL databases (see Methods). These analyses
connected novel SNPs to transcript abundance of SYPL2,
SDCCAG8, MANBA, KBTBD2, PTPRO and SPATA33
(C16orf55), thereby supporting these as potential candidate
genes in the respective associated regions (Supplementary
Table 11).
Pathway analyses. We used a novel method, Data-driven
Expression Prioritized Integration for Complex Traits (DEPICT)23,
to prioritize genes at associated loci, to test whether genes at
associated loci are highly expressed in speciﬁc tissues or cell types
and to test whether speciﬁc biological pathways and gene sets are
enriched for genes in associated loci. On the basis of all SNPs with
eGFRcrea association P values o10 5 in the discovery meta-
analysis, representing 124 independent regions, we identiﬁed at
least one signiﬁcantly prioritized gene in 49 regions, including in 9
of the 24 novel genome-wide signiﬁcant regions (Supplementary
Table 12). Five tissue and cell type annotations were enriched for
expression of genes from the associated regions, including the
kidney and urinary tract, as well as hepatocytes and adrenal glands
and cortex (Fig. 3a; Supplementary Table 13). Nineteen
reconstituted gene sets showed enrichment of genes mapping
into the associated regions at a permutation P value o10 5
(Supplementary Table 14; Fig. 4), highlighting processes related to
renal development, kidney transmembrane transporter activity,
kidney and urogenital system morphology, regulation of glucose
metabolism, as well as speciﬁc protein complexes important in
renal development.
Table 1 | The 24 novel SNPs associated with eGFRcrea in European ancestry individuals.
SNP ID* Chr. Position (bp)w Locus
namez
Effect/Non
effect allele
(EAF)
SNP
functiony
Stage 1
(discovery)||
Stage 2
(replication)
Combined analysisz
Beta P value Beta q-value Beta P value# I2 %**
The eight loci whose smallest P value was observed in the ‘no diabetes’ group
rs3850625 1 201,016,296 CACNA1S A/G (0.12) Exonic,
nonsyn. SNV
0.0080 2.55E09 0.0071 5.46E03 0.0083 6.82E 11 0
rs2712184 2 217,682,779 IGFBP5 A/C (0.58) Intergenic 0.0049 1.65E08 0.0055 2.06E03 0.0053 1.33E 10 0
rs9682041 3 170,091,902 SKIL T/C (0.87) Intronic 0.0067 1.36E07 0.0046 2.33E02 0.0068 2.58E08 2
rs10513801 3 185,822,353 ETV5 T/G (0.87) Intronic 0.0070 3.80E09 0.0046 1.79E02 0.0072 1.03E09 0
rs10994860 10 52,645,424 A1CF T/C (0.19) UTR5 0.0075 1.00E 11 0.0061 5.46E03 0.0077 1.07E 12 2
rs163160 11 2,789,955 KCNQ1 A/G (0.82) Intronic 0.0067 9.02E09 0.0050 9.89E03 0.0065 2.26E09 14
rs164748 16 89,708,292 DPEP1 C/G (0.53) Intergenic 0.0047 9.92E09 0.0019 4.19E02 0.0046 1.95E08 17
rs8091180 18 77,164,243 NFATC1 A/G (0.56) Intronic 0.0054 1.43E08 0.0052 5.46E03 0.0060 1.28E09 0
The 16 loci whose smallest P value was observed in the ‘overall’ group
rs12136063 1 110,014,170 SYPL2 A/G (0.70) Intronic 0.0049 2.33E07 0.0028 2.31E02 0.0045 4.71E08 0
rs2802729 1 243,501,763 SDCCAG8 A/C (0.43) Intronic 0.0050 7.37E08 0.0029 2.05E02 0.0046 2.20E08 9
rs4667594 2 170,008,506 LRP2 A/T (0.53) Intronic 0.0045 2.37E07 0.0043 5.62E03 0.0044 3.52E08 4
rs6795744ww 3 13,906,850 WNT7A A/G (0.15) Intronic 0.0071 9.60E09 0.0019 5.15E02 0.0060 3.33E08 18
rs228611 4 103,561,709 NFKB1 A/G (0.47) Intronic 0.0055 4.66E 10 0.0060 8.91E04 0.0056 3.58E 12 3
rs7759001 6 27,341,409 ZNF204 A/G (0.76) ncRNA
intronic
0.0053 2.64E07 0.0045 9.10E03 0.0051 1.75E08 0
rs10277115 7 1,285,195 UNCX A/T (0.23) Intergenic 0.0095 1.05E 10 0.0079 9.03E04 0.0090 8.72E 14 0
rs3750082 7 32,919,927 KBTBD2 A/T (0.33) Intronic 0.0049 2.52E07 0.0031 1.96E02 0.0045 3.22E08 2
rs6459680 7 156,258,568 RNF32 T/G (0.74) Intergenic 0.0065 1.96E 10 0.0019 4.62E02 0.0055 1.07E09 0
rs4014195 11 65,506,822 AP5B1 C/G (0.64) Intergenic 0.0061 2.19E 11 0.0034 1.42E02 0.0055 1.10E 11 0
rs10491967 12 3,368,093 TSPAN9 A/G (0.10) Intronic 0.0092 3.03E 10 0.0106 3.93E04 0.0095 5.18E 14 0
rs7956634 12 15,321,194 PTPRO T/C (0.81) Intronic 0.0068 2.46E09 0.0069 1.51E03 0.0068 7.17E 12 0
rs1106766 12 57,809,456 INHBC T/C (0.22) Intergenic 0.0062 4.67E08 0.0058 8.79E03 0.0061 2.41E09 9
rs11666497 19 38,464,262 SIPA1L3 T/C (0.18) Intronic 0.0064 8.58E08 0.0041 1.53E02 0.0058 4.25E08 24
rs6088580 20 33,285,053 TP53INP2 C/G (0.47) Intergenic 0.0055 7.17E 10 0.0027 2.31E02 0.0049 1.79E09 0
rs17216707 20 52,732,362 BCAS1 T/C (0.79) Intergenic 0.0084 5.96E 13 0.0051 6.69E03 0.0077 8.83E 15 1
bp, basepairs; Chr, chromosome; EAF, effect allele frequency; eGFRcrea, eGFR based on serum creatinine; GWAS, genome-wide association studies; SNP, single-nucleotide polymorphism;
UTR, untranslated region.
*SNPs are grouped by the stratum where the smallest P value in the discovery and combined analysis was observed. In the ‘no diabetes’ group, sample size/number of studies were equal to 118,448/45,
36,433/13 and 154,881/58, in the discovery, replication and combined analyses, respectively. In the ‘overall’ group, the numbers for the three analyses were equal to 133,413/48, 42,116/14 and
175,579/62, respectively.
wOn the basis of RefSeq genes (build 37).
zConventional locus name based on relevant genes in the region as identiﬁed by bioinformatic investigation (Supplementary Table 12) or closest gene. A complete overview of the genes in each locus is
given in the regional association plots (Supplementary Fig. 4).
ySNP function is derived from NCBI RefSeq genes and may not correspond to the named gene.
||Twice genomic-control (GC) corrected P value from discovery GWAS meta-analysis: at the individual study level and after the meta-analysis.
zFor random-effect estimate, see Supplementary Table 4.
#P value of the meta-analysis of the twice GC-corrected discovery meta-analysis results and replication studies.
**Between-study heterogeneity, as assessed by the I2. Q statistic P value 40.05 for all SNPs, except rs11666497 (SIPA1L3, P value¼0.04).
wwFor this SNP, the conditions for replication were not all met (q-value 40.05 in the replication stage).
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DNase I hypersensitivity and H3K4m3 chromatin mark analyses.
To evaluate whether eGFRcrea-associated SNPs map into gene
regulatory regions and to thereby gain insight into their potential
function, we evaluated the overlap of independent eGFRcrea-
associated SNPs with P values o10 4 (or their proxies) with
DHSs using publicly available data from the Epigenomics Road-
map Project and ENCODE for 123 cell types (see Methods).
DHSs mark accessible chromatin regions where transcription
may occur. Compared with a set of control SNPs (see Methods),
eGFRcrea-associated SNPs were signiﬁcantly more likely to map
to DHS in six speciﬁc tissues or cell types (Fig. 3b), including
adult human renal cortical epithelial cells, adult renal proximal
tubule epithelial cells, H7 embryonic stem cells (differentiated 2
days), adult human renal epithelial cells, adult small airway epi-
thelial cells and amniotic epithelial cells. No signiﬁcant enrich-
ment was observed for adult renal glomerular endothelial cells,
the only other kidney tissue evaluated.
Next, we analysed the overlap of the same set of SNPs with
H3K4me3 chromatin marks, promoter-speciﬁc histone modiﬁca-
tions associated with active transcription24, in order to gather
more information about cell-type speciﬁc regulatory potential of
eGFRcrea-associated SNPs. Comparing 33 available adult-derived
cell types, we found that eGFRcrea-associated SNPs showed the
most signiﬁcant overlap with H3K4me3 peaks in adult kidney (P
value¼ 0.0029), followed by liver (P value¼ 0.0117), and rectal
mucosa (P value¼ 0.0445). Taken together, these ﬁndings are
suggestive of cell-type-speciﬁc regulatory roles for eGFR loci, with
greatest speciﬁcity for the kidney.
Chromatin annotation maps. In addition to assessing individual
regulatory marks separately, we annotated the known and repli-
cated novel SNPs, as well as their perfect proxies in a com-
plementary approach. Chromatin annotation maps were
generated integrating 410 epigenetic marks from cells derived
from adult human kidney tissue and a variety of non-renal tissues
from the ENCODE project (see Methods). The proportion of
variants to which a function could be assigned was signiﬁcantly
higher when using chromatin annotation maps from renal tissue
compared with using maps that investigated the same epigenetic
marks in other non-renal tissues (Fig. 3c), again indicating that
eGFRcrea associated SNPs are, or tag, kidney-speciﬁc regulatory
variants. The difference between kidney and non-renal tissues
was particularly evident for marks that deﬁne enhancers: the
proportion of SNPs mapping to weak and strong enhancer
regions in the kidney tissue was higher than in all non-kidney
tissues (Fishers’ exact test P values from 3.1 10 3 to
7.9 10 6, multiple testing threshold a¼ 5.6 10 3).
Functional characterization of new loci. To prioritize genes for
functional studies, we applied gene prioritization algorithms
including GRAIL25, DEPICT and manual curation of selected
genes in each region (Supplementary Table 12). For each region,
gene selection criteria were as follows: (1) either GRAIL P value
o0.05 or DEPICT false discovery rate (FDR) o0.05; (2) the
effect of a given allele on eGFRcrea and on eGFRcys was
direction-consistent and their ratio was between 0.2 and 5
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Figure 2 | Association eGFRcrea loci in subjects with and without diabetes. Novel (a) and known (b) loci were considered. Displayed are effects and their
95% conﬁdence intervals on ln(eGFRcrea). Results are sorted by increasing effects in the diabetes group. The majority of loci demonstrated similar effect
sizes in the diabetes as compared with non-diabetes strata. SNP-speciﬁc information and detailed sample sizes are reported in Supplementary Table 5.
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(to ensure relative homogeneity of the beta coefﬁcients); (3)
nearest gene if the signal was located in a region containing a
single gene. Using this approach, NFKB1, DPEP1, TSPAN9,
NFATC1, WNT7A, PTPRO, SYPL2, UNCX, KBTBD2, SKIL and
A1CF were prioritized as likely genes underlying effects at the
new loci (Supplementary Table 12).
We investigated the role of these genes during vertebrate
kidney development by examining the functional consequences of
gene knockdown in zebraﬁsh embryos utilizing antisense
morpholino oligonucleotide (MO) technology. After knockdown,
we assessed the expression of established renal markers pax2a
(global kidney), nephrin (podocytes) and slc20a1a (proximal
tubule) at 48 hours post fertilization by in situ hybridization12. In
all cases, morphant embryos did not display signiﬁcant gene
expression defects compared with controls (Supplementary
Table 15).
Discussion
We identiﬁed 24 new loci in association with eGFR and
conﬁrmed 29 previously identiﬁed loci. A variety of
complementary analytic, bioinformatic and functional
approaches indicate enrichment of implicated gene products in
kidney and urinary tract tissues. A greater proportion of the lead
SNPs or their perfect proxies map into gene regulatory regions,
speciﬁcally enhancers, in adult renal tissues compared with non-
renal tissues. In addition to the importance in the adult kidney,
our results indicate a role for kidney function variants during
development.
We extend our previous ﬁndings, as well as those from other
groups7–13 by identifying 450 genomic loci for kidney function,
many of which were not previously known to be connected to
kidney function and disease. Using a discovery data set that is
nearly double in size to our prior effort7, we are now able to
robustly link associated SNPs to kidney-speciﬁc gene regulatory
function. Our work further exempliﬁes the continued value of
increasing the sample size of GWAS meta-analyses to uncover
additional loci and gain novel insights into the mechanisms
underlying common phenotypes26.
There are several messages from our work. First, many of the
genetic variants associated with eGFR appear to affect processes
speciﬁcally within the kidney. The kidney is a highly vascular and
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enrichment of variants mapping to enhancer regions speciﬁcally in kidney but not other non-renal tissues.
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metabolically active organ that receives 20% of all cardiac output,
contains an extensive endothelium-lined capillary network, and is
sensitive to ischaemic and toxic injury. As a result, hypertension,
cardiovascular diseases and diabetes each affect renal hemody-
namics and contribute to kidney injury. However, many of the
eGFR-associated SNPs in our GWAS could be assigned gene
regulatory function speciﬁcally in the kidney and its epithelial
cells, but not in human glomerular endothelial cells or the general
vasculature. In addition, variants associated with eGFR were not
associated with vascular traits, such as blood pressure or
myocardial infarction. Taken together, these ﬁndings suggest
that genetic determinants of eGFR may be mediated largely
through direct effects within the kidney.
Second, despite the speciﬁcity related to renal processes, we
also identiﬁed several SNPs that are associated with eGFR in
diabetes, and our pathway analyses uncovered gene sets
associated with glucose transporter activity and abnormal glucose
homeostasis. Uncovering bona ﬁde genetic loci for diabetic CKD
has been difﬁcult. We have now identiﬁed a total of 19 SNPs that
demonstrate at least nominal association with eGFR in diabetes.
The diabetes population is at particularly high risk of CKD, and
identifying kidney injury pathways may help develop new
treatments for diabetic CKD.
Finally, even though CKD is primarily a disease of the elderly,
our pathway enrichment analyses highlight developmental
processes relevant to the kidney and the urogenital tract. Kidney
disease has been long thought to have developmental origins, in
part related to early programming (Barker hypothesis)27, low
birth weight, nephron endowment and early growth and early-life
nutrition28. Our pathway enrichment analyses suggest that
developmental pathways such as placental morphology, kidney
weight and embryo size, as well as protein complexes of
importance in renal development may in part contribute to the
developmental origins of CKD.
A limitation of our work is that causal variants and precise
molecular mechanisms underlying the observed associations were
not identiﬁed and will require additional experimental follow-up
projects. Our attempt to gain insights into potentially causal
genes through knockdown in zebraﬁsh did not yield any clear
CKD candidate gene, although the absence of a zebraﬁsh
phenotype upon gene knockdown does not mean that the gene
cannot be the one underlying the observed association signal in
humans. Finally, our conclusions that eGFRcrea-associated SNPs
regulate the expression of nearby genes speciﬁcally in kidney
epithelial cells are based on DHSs, H3K4me3 chromatin marks
and chromatin annotation maps. Since these analyses rely mostly
on variant positions, additional functional investigation such as
luciferase assay that assess transcriptional activity more directly
are likely to gain additional insights into the variants’ mechanism
of action.
The kidney speciﬁcity for loci we identiﬁed may have
important translational implications, particularly since our DHS
and chromatin annotation analyses suggest that at least a set of
gene regulatory mechanisms is important in the adult kidney.
Kidney-speciﬁc pathways are important for the development of
novel therapies to prevent and treat CKD and its progression with
minimal risk of toxicity to other organs. Finally, the biologic
insights provided by these new loci may help elucidate novel
mechanisms and pathways implicated not only in CKD but also
of kidney function in the physiological range.
In conclusion, we have conﬁrmed 29 genomic loci and
identiﬁed 24 new loci in association with kidney function that
together highlight target organ-speciﬁc regulatory mechanisms
related to kidney function.
Methods
Overview. This was a collaborative meta-analysis with a distributive data model.
Brieﬂy, an analysis plan was created and circulated to all participating studies. Studies
then uploaded study-speciﬁc data centrally; ﬁles were cleaned, and a speciﬁc
meta-analysis for each trait was performed. Details regarding each step are
provided below. All participants in all discovery and replication studies provided
informed consent. Each study had its research protocol approved by the local
ethics committee.
Phenotype deﬁnitions. Serum creatinine was measured in each discovery and
replication study as described in Supplementary Tables 16 and 17, and statistically
calibrated to the US nationally representative National Health and Nutrition
Examination Study data in all studies to account for between-laboratory varia-
tion9,29,30. eGFRcrea was estimated using the four-variable Modiﬁcation of Diet in
Renal Disease Study Equation. Cystatin C, an alternative biomarker for kidney
function, was measured in a sub-set of participating studies. eGFRcys was estimated
as 76.7 (serum cystatin C) 1.19 (ref. 31). eGFRcrea and eGFRcys values
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Figure 4 | Gene set overlap analysis. The 19 reconstituted gene sets with P valueo10 5 were considered. Their overlap was estimated by computing the
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o15mlmin per 1.73m2 were set to 15, and those4200 were set to 200mlmin 1
per 1.73m2. CKD was deﬁned as eGFRcrea o60ml min 1 per 1.73m2.
Diabetes was deﬁned as fasting glucose Z126mg dl 1, pharmacologic
treatment for diabetes or by self-report. In all studies, diabetes and kidney function
were assessed at the same point in time.
Genotypes. Genotyping was conducted in each study as speciﬁed in
Supplementary Tables 18 and 19. After applying appropriate quality ﬁlters, 45
studies used markers of highest quality to impute B2.5 million SNPs, based on
European-ancestry haplotype reference samples (HapMap II CEU). Four studies
based their imputation on the 1000 Genomes Project data. Imputed genotypes were
coded as the estimated number of copies of a speciﬁed allele (allelic dosage).
Genome-wide association analysis. By following a centralized analysis plan, each
study regressed sex- and age-adjusted residuals of the logarithm of eGFRcrea or
eGFRcys on SNP dosage levels. Logistic regression of CKD status was performed
on SNP dosage levels adjusting for sex and age. For all traits, adjustment for
appropriate study-speciﬁc features, including study site and genetic principal
components was included in the regression and family-based studies appropriately
accounted for relatedness.
Stage 1 discovery meta-analysis. GWAS of eGFRcrea were contributed by 48
studies (total sample size, N¼ 133,413); 45 studies contributed GWAS data for the
non-diabetes subgroup (N¼ 118,448) and 39 for the diabetes group (N¼ 11,522).
GWAS of CKD were comprised by 43 studies, for a total sample size of 117,165,
including 12,385 CKD cases. GWAS of eGFRcys were comprised by 16 studies for a
total sample size of 32,834. All GWAS ﬁles underwent quality control using the
GWAtoolbox package32 in R, before including them into the meta-analysis.
Genome-wide meta-analysis was performed with the software METAL33, assuming
ﬁxed effects and using inverse-variance weighting. The genomic inﬂation factor l
was estimated for each study as the ratio between the median of all observed test
statistics (b/s.e.)2 and the expected median of a w2 with 1 degree of freedom, with b
and s.e. representing the effect of each SNP on the phenotype and its standard
error, respectively34. Genomic-control (GC) correction was applied to P values and
s.e.’s in case of l41 (ﬁrst GC correction). SNPs with an average minor allele
frequency (MAF) ofZ0.01 were used for the meta-analysis. To limit the possibility
of false positives, after the meta-analysis, a second GC correction on the aggregated
results was applied. Between-study heterogeneity was assessed through the I2
statistic.
After removing SNPs with MAF of o0.05 and which were available in o50%
of the studies, SNPs with a P value of r10 6 were selected and clustered into
independent loci through LD pruning based on an r2 of r0.2 within a window of
±1MB to each side of the index SNP. After removing loci containing variants that
have been previously replicated at a P value of 5.0 10 8 (refs 7,8), the SNP with
the lowest P value within each locus was selected for replication (‘index SNP’). If a
SNP had an association P value ofr10 6 with more than one trait, the trait where
the SNP had the lowest P value was selected as discovery trait/stratum. Altogether,
this resulted in 48 SNPs: 34 from eGFRcrea, 9 from eGFRcrea among those without
diabetes, 4 from CKD and 1 from eGFRcys.
Stage 2 replication analysis. In silico replication analysis for any of the studied
traits was carried out using eight independent studies whose genotyping platforms
are provided in Supplementary Table 19. De novo genotyping was performed in
seven additional studies (N¼ 22,850 individuals) of European ancestry
(Supplementary Table 20), including the Bus Sante´, ESTHER, KORA-F3 (subset of
F3 without GWAS), KORA-F4 (subset of F4 without GWAS), Ogliastra Genetic
Park (OGP, without Talana whose GWAS was included in the discovery analysis),
SAPHIR and SKIPOGH studies (Supplementary Table 20). Summarizing all in
silico and de novo replication studies (Supplementary Table 1), replication data for
eGFRcrea were contributed by 14 studies (total sample size¼ 42,166), which also
contributed eGFRcrea results from non-diabetes (13 studies, N¼ 36,433) and
diabetes samples (13 studies, N¼ 4,955). Thirteen studies contributed replication
data on CKD (N¼ 33,972; 4,245 CKD cases; studies with o50 CKD cases were
excluded) and ﬁve on eGFRcys (N¼ 14,930).
Association between eGFRcrea, CKD and eGFRcys and each of the 48 SNPs in
the replication studies was assessed using the same analysis protocol detailed for
the discovery studies above. Quality control of the replication ﬁles was performed
with the same software as described above.
We performed a combined ﬁxed-effect meta-analysis of the double-GC
corrected results from the discovery meta-analysis and the replication studies,
based on inverse-variance weighting. The total sample size in the combined
analysis of eGFRcrea was 175,579 subjects (154,881 in the non-diabetes stratum
and 16,477 in the diabetes stratum; the sum of these two sample sizes is smaller
than the sample size of the overall analysis because some studies did not contribute
both strata), 151,137 samples for CKD (16,630 CKD cases) and 47,764 for
eGFRcys. Three criteria were used to ensure validity of novel loci declared as
signiﬁcant: (1) P value from the combined meta-analysis r5.0 10 8 in
accordance with previously published guidelines35; (2) direction-consistent
associations of the beta coefﬁcients in stage 1 and stage 2 (one-sided P values were
estimated to test for consistent effect direction with the discovery stage); (3) q-value
o0.05 in the replication stage. Q-values were estimated using the package
QVALUE36 in R. The tuning parameter lambda for the estimation of the overall
proportion of true null hypotheses, p0, was estimated using the bootstrap
method37. When the third criterion was not satisﬁed, the locus was declared
‘suggestive’.
Power analysis. With the sample size achieved in the combined analysis of stage 1
and stage 2 data, the power to assess replication at the canonical genome-wide
signiﬁcance level of 5.0 10 8 was estimated with the software QUANTO38
version 1.2.4, assuming the same MAF and effect size observed in the discovery
sample. Power to replicate associations ranged from 87 to 100% for eGFRcrea
associated SNPs (median¼ 98%), from 72 to 96% for the CKD-associated SNPs,
and was equal to 59% for the eGFRcys-associated SNP (Supplementary Table 3).
Associations stratiﬁed by diabetes and hypertension status. For all the 24
novel and 29 known SNPs, the difference between the SNP effect on eGFRcrea in
the diabetes versus the non-diabetes groups was assessed by means of a two-sample
t-test for correlated data at a signiﬁcance level of 0.05. We used the following two-
sample t-test for correlated data:
t ¼ bDM  bnonDMð Þ
s:e: bDMð Þ2 þ s:e: bnonDMð Þ2  2r bDM; bnonDMð Þs:e: bDMð Þs:e: bnonDMð Þ
 0:5 ;
where bDM and bnonDM represent the SNP effects on log(eGFRcrea) in the two
groups, s.e. is the standard error of the estimate and r(.) indicates the correlation
between effects in the two groups, which was estimated as 0.044 by sampling
100,000 independent SNPs from our DM and nonDM GWAS, after removing
known and novel loci associated with eGFRcrea. For a large sample size, as in our
case, t follows a standard normal distribution.
A similar analysis was performed to compare results in subjects with and
without hypertension, based on results from our previous work7. The correlation
between the two strata was of 0.01.
Proportion of phenotypic variance explained. The percent of phenotypic
variance explained by novel and known loci was estimated as
P53
i¼1
R2i , where
R2i ¼ b2i varðSNPiÞ=varðyÞ is the coefﬁcient of determination for each of the 53
individual SNPs associated with eGFRcrea uncovered to date (24 novel and 29
known ones), bi is the estimated effect of the ith SNP on y, y corresponds to the sex-
and age-adjusted residuals of the logarithm of eGFRcrea and var(SNPi)¼ 2
MAFSNPi (1MAFSNPi)39. Var(y) was estimated in the ARIC study and all loci
were assumed to have independent effects on the phenotype.
Test for SNP associations with related traits. We performed evaluations of SNP
association with results generated from consortia investigating other traits. Speci-
ﬁcally, we evaluated systolic and diastolic blood pressure in ICBP17, myocardial
infarction in CARDiOGRAM18, left ventricular mass19, heart failure20, the urinary
albumin to creatinine ratio (CKDGen consortium, personal communication) and
fasting plasma glucose in MAGIC21. In total, we performed 165 tests,
corresponding to 7 traits tested for association against each of the 24 novel SNP,
with the exception of myocardial infarction for which results from 3 SNPs were not
available (Supplementary Table 6). Signiﬁcance was evaluated at the Bonferroni
corrected level of 0.05/165¼ 0.0003.
Lookup of replicated loci in the NHGRI GWAS catalog. All replicated SNPs, as
well as SNPs in LD (r240.2) within ±1MB distance were checked for their
association with other traits according to the NHGRI GWAS catalog40 (accessed
April 14, 2014).
SNP assessments in other ethnic groups. We performed cross-ethnicity SNP
evaluations in participants of African ancestry from a meta-analysis of African
ancestry individuals and from participants of Asian descent from the AGEN
consortium11.
African ancestry meta-analysis. We performed ﬁxed-effect meta-analysis of the
genome-wide association data from 12 African ancestry studies (Supplementary
Table 8) with imputation to HapMap reference panel, based on inverse-variance
weighting using METAL. Only SNPs with MAF Z0.01 and imputation quality
r2Z0.3 were considered for the meta-analysis. After meta-analysis, we removed
SNPs with MAF o0.05 and which were available in o50% of the studies. Sta-
tistical signiﬁcance was assessed at the standard threshold of 5.0 10 8. Genomic
control correction was applied at both the individual study level before meta-
analysis and after the meta-analysis.
Transethnic meta-analysis. We performed a trans-ethnic meta-analysis of GWAS
data from cohorts of different ethnic backgrounds using MANTRA (Meta-Analysis
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of Trans-ethnic Association studies) software22. We combined the 48 European
ancestry studies that contributed eGFRcrea, which were included in stage 1
discovery meta-analysis, and the 12 African ancestry studies mentioned above for a
total sample size of 150,253 samples. We limited our analysis to biallelic SNPs with
MAF Z0.01 and imputation quality r2Z0.3. Relatedness between the 60 studies
was estimated using default settings from up to 5.9 million SNPs. Only SNPs that
were present in more than 25 European ancestry studies and 6 African ancestry
studies (total sample sizeZ120,000) were considered after meta-analysis. Genome-
wide signiﬁcance was deﬁned as a log10 Bayes’ Factor (log10BF) Z6 (ref. 41).
Gene Relationships Across Implicated Loci (GRAIL). To prioritize the gene(s)
most likely to give rise to association signals in a given region, the software GRAIL
was used25. The index SNP of all previously known kidney function associated
regions, as well as the novel SNPs identiﬁed here was used as input, using the CEU
HapMap (hg18 assembly) and the functional datasource text_2009_03, established
before the publication of kidney function-related GWAS. Results from GRAIL were
used to prioritize genes for follow-up functional work.
Expression quantitative trait loci analysis. We identiﬁed alias rsIDs and proxies
(r240.8) for our index SNPs using SNAP software across 4 HapMap builds. SNP
rsIDs and aliases were searched for primary SNPs and LD proxies against a
collected database of expression SNP (eSNP) results. The collected eSNP results
met criteria for statistical thresholds for association with gene transcript levels in
their respective original analyses (for references see Supplementary Table 11).
Correlation of selected eSNPs to the best eSNPs per transcript per expression
quantitative trait loci (eQTL) data set were assessed by pairwise LD. All results
are reported in Supplementary Table 11.
DEPICT analysis. In this work, we ﬁrst used PLINK42 to identify independently
associated SNPs using all SNPs with eGFRcrea association P values o10 5
(HapMap release 27 CEU data43; LD r2 threshold¼ 0.01; physical kb threshold
¼ 1,000). We then used the DEPICT method23 to construct associated regions by
mapping genes to independently associated SNPs if they overlapped or resided
within LD (r240.5) distance of a given associated SNP. After merging overlapping
regions and discarding regions that mapped within the major histocompatibility
complex locus (chromosome 6, base pairs 20,000,000–40,000,000), 124 non-
overlapping regions remained that covered a total of 320 genes. Finally, we ran the
DEPICT software program on the 124 regions to prioritize genes that may
represent promising candidates for experimental follow up studies, identify
reconstituted gene sets that are enriched in genes from associated regions and
therefore may provide insight into general kidney function biology, and identify
tissue and cell-type annotations in which genes from associated regions are highly
expressed. Speciﬁcally, for each tissue, the DEPICT method performs a t-test
comparing the tissue-speciﬁc expression of eGFRcrea-associated genes and all
other genes. Next, for each tissue, empirical enrichment P values are computed by
repeatedly sampling random sets of loci (matched to the actual eGFRcrea loci by
gene density) from the entire genome to estimate the empirical mean and s.d. of the
enrichment statistic’s null distribution. To visualize the nineteen reconstituted gene
sets with P value o1e 5 (Fig. 4), we estimated their overlap by computing the
pairwise Pearson correlation coefﬁcient r between each pair of gene sets followed
by discretization into one of three bins; 0.3rro0.5, low overlap; 0.5rro0.7,
medium overlap; rZ0.7, high overlap.
DNase I hypersensitivity analysis. The overlap of SNPs associated with eGFR-
crea at Po10 4 with DHSs was examined using publically available data from the
Epigenomics Roadmap Project and ENCODE. In all, DHS mappings were
available for 123 mostly adult cells and tissues44 (downloaded from http://
hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeUwDnase/).
The analysis here pertains to DHS’s deﬁned as ‘broad’ peaks, which were available
as experimental replicates (typically duplicates) for the majority of cells and tissues.
SNPs from our stage 1 eGFRcrea GWAS meta-analysis were ﬁrst clumped in
PLINK42 in windows of 100 kb and maximum r2 of 0.1 using LD relationships
from the 1,000 Genomes EUR panel (phase I, v3, 3/14/2012 haplotypes) using a
series of P value thresholds (10 4, 10 6, 10 8, ... and 10 16). LD proxies of the
index SNPs from the clumping procedure were then identiﬁed by LD tagging in
PLINK with r2¼ 0.8 in windows of 100 kb, again using LD relationships in the
1000G EUR panel, restricted to SNPs with MAF 41% and also present in the
HapMap2 CEU population. A reference set of control SNPs was constructed using
the same clumping and tagging procedures applied to NHGRI GWAS catalog SNPs
(available at http://www.genome.gov/gwastudies/, accessed 13 March 2013) with
discovery P values o5.0 10 8 in European populations. In total, there were
1,204 such reference SNPs after LD pruning. A small number of reference SNPs or
their proxies overlapping with the eGFRcrea SNPs or their proxies were excluded.
For each cell-type and P value threshold, the enrichment of eGFR SNPs (or their
LD proxies) mapping to DHSs relative to the GWAS catalog reference SNPs (or
their LD proxies) was expressed as an odds ratio from logistic mixed effect models
that treated the replicate peak determinations as random effects (lme4 package
in R). Signiﬁcance for enrichment odds ratio was derived from the signiﬁcance of
beta coefﬁcients for the main effects in the mixed models.
Interrogation of human kidney chromatin annotation maps. Different chro-
matin modiﬁcation patterns can be used to generate tissue-speciﬁc chromatin-state
annotation maps. These can serve as a valuable resource to discover regulatory
regions and study their cell-type-speciﬁc distributions and activities, which may
help with the interpretation especially of intergenic variants identiﬁed in associa-
tion studies45. We therefore investigated the genomic mapping of the known and
replicated novel index SNPs, as well as their perfect LD proxies (n¼ 173, r2¼ 1 for
proxies) using a variety of resources, including chromatin maps generated from
human kidney tissue cells (HKC-E cells). Chromatin immune-precipitation
sequencing (ChIP-seq) data from human kidney samples were generated by NIH
Roadmap Epigenomics Mapping Consortium46. Brieﬂy, proximal tubule cells
derived from an adult human kidney were collected and cross-linked with 1%
formaldehyde. Subsequently, ChIP-seq was conducted using whole-cell extract
from adult kidney tissue as the input (GSM621638) and assessing the following
chromatin marks: H3K36me3 (GSM621634), H3K4me1 (GSM670025), H3K4me3
(GSM621648), H3K9ac (GSM772811) and H3K9me3 (GSM621651). The MACS
version 1.4.1 (model-based analysis of ChIP-Seq) peak-ﬁnding algorithm was used
to identify regions of ChIP-Seq enrichment47. A FDR threshold of enrichment of
0.01 was used for all data sets. The resulting genomic coordinates in bed format
were further used in ChromHMM v1.06 for chromatin annotation45. For
comparison, the same genomic coordinates were investigated in chromatin
annotation maps of renal tissue, as well as across nine different cell lines from the
ENCODE Project: umbilical vein endothelial cells (HUVEC), mammary epithelial
cells (HMEC), normal epidermal keratinocytes (NHEK), B-lymphoblastoid cells
(GM12878), erythrocytic leukemia cells (K562), normal lung ﬁbroblasts (NHLF),
skeletal muscle myoblasts (HSMM), embryonic stem cells (H1 ES) and
hepatocellular carcinoma cells (HepG2). We tested whether the proportion of SNPs
pointing to either strong or weak enhancers in the human kidney tissue cells was
different from that of the other nine tissues by means of a Fishers’ exact test for
2 2 tables, contrasting each of the nine cell lines listed above against the reference
kidney cell line, at a Bonferroni-corrected signiﬁcance level of 0.05/9¼ 5.6 10 3.
Functional characterization of new loci. Replicated gene regions were prioritized
for functional studies using the following criteria: (1) GRAIL identiﬁcation of a
gene in each region of P valueo0.05 or DEPICT, FDRo0.05); (2) an eGFRcrea to
eGFRcys ratio between 0.2 and 5 with direction consistency between the beta
coefﬁcients; (3) nearest gene if the signal was located in a gene-poor region. The list
of genes selected for functional work can be found in Supplementary Table 12. This
same prioritization scheme was also used to assign locus names. Morpholino
knockdowns were performed in zebraﬁsh.
Zebraﬁsh (strain Tu¨bingen, TU) were maintained according to established
Harvard Medical School Institutional Animal Care and Use Committee protocols
(protocol # 04626). Male and female ﬁsh were mated (age 6–12 months) for
embryo production. Embryos were injected at the one-cell stage with MOs
(GeneTools) designed to block either the ATG start site or an exon–intron splice
site of the target gene (Supplementary Table 21). In cases where human loci are
duplicated in zebraﬁsh, both orthologues were knocked down simultaneously by
combination MO injection. MOs were injected in escalating doses at
concentrations up to 250 mM. Embryos were ﬁxed in 4% paraformaldehyde at 48 h
post fertilization for in situ hybridization using published methods (http://zﬁn.org/
ZFIN/Methods/ThisseProtocol.html). Gene expression was visualized using
established renal markers pax2a (global kidney), nephrin (podocytes) and slc20a1a
(proximal tubule). The number of morphant embryos displaying abnormal gene
expression was compared with control embryos by means of a Fisher’s exact test.
References
1. Eckardt, K. U. et al. Evolving importance of kidney disease: from subspecialty
to global health burden. Lancet 382, 158–169 (2013).
2. El Nahas, M. The global challenge of chronic kidney disease. Kidney Int. 68,
2918–2929 (2005).
3. Baumeister, S. E. et al. Effect of chronic kidney disease and comorbid
conditions on health care costs: A 10-year observational study in a general
population. Am. J. Nephrol. 31, 222–229 (2010).
4. Fox, C. S. et al. Associations of kidney disease measures with mortality and
end-stage renal disease in individuals with and without diabetes: a meta-
analysis. Lancet 380, 1662–1673 (2012).
5. Mahmoodi, B. K. et al. Associations of kidney disease measures with mortality
and end-stage renal disease in individuals with and without hypertension:
a meta-analysis. Lancet 380, 1649–1661 (2012).
6. Himmelfarb, J. & Tuttle, K. R. New therapies for diabetic kidney disease. N.
Engl. J. Med. 369, 2549–2550 (2013).
7. Pattaro, C. et al. Genome-wide association and functional follow-up reveals
new loci for kidney function. PLoS Genet. 8, e1002584 (2012).
8. Kottgen, A. et al. New loci associated with kidney function and chronic kidney
disease. Nat. Genet. 42, 376–384 (2010).
9. Kottgen, A. et al. Multiple loci associated with indices of renal function and
chronic kidney disease. Nat. Genet. 41, 712–717 (2009).
10. Chambers, J. C. et al. Genetic loci inﬂuencing kidney function and chronic
kidney disease. Nat. Genet. 42, 373–375 (2010).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10023 ARTICLE
NATURE COMMUNICATIONS | 7:10023 | DOI: 10.1038/ncomms10023 | www.nature.com/naturecommunications 9
11. Okada, Y. et al. Meta-analysis identiﬁes multiple loci associated with kidney
function-related traits in east Asian populations. Nat. Genet. 44, 904–909
(2012).
12. Liu, C. T. et al. Genetic association for renal traits among participants of
African ancestry reveals new loci for renal function. PLoS Genet. 7, e1002264
(2011).
13. Boger, C. A. et al. Association of eGFR-Related Loci Identiﬁed by GWAS with
Incident CKD and ESRD. PLoS Genet. 7, e1002292 (2011).
14. Chasman, D. I. et al. Integration of genome-wide association studies with
biological knowledge identiﬁes six novel genes related to kidney function. Hum.
Mol. Genet. 21, 5329–5343 (2012).
15. Pattaro, C. et al. A meta-analysis of genome-wide data from ﬁve European
isolates reveals an association of COL22A1, SYT1, and GABRR2 with serum
creatinine level. BMC Med. Genet. 11, 41 (2010).
16. Trudu, M. et al. Common noncoding UMOD gene variants induce salt-
sensitive hypertension and kidney damage by increasing uromodulin
expression. Nat. Med. 19, 1655–1660 (2013).
17. International Consortium for Blood Pressure Genome-Wide Association
Studies et al. Genetic variants in novel pathways inﬂuence blood pressure and
cardiovascular disease risk. Nature 478, 103–109 (2011).
18. Schunkert, H. et al. Large-scale association analysis identiﬁes 13 new
susceptibility loci for coronary artery disease. Nat. Genet. 43, 333–338 (2011).
19. Vasan, R. S. et al. Genetic variants associated with cardiac structure and
function: a meta-analysis and replication of genome-wide association data.
JAMA 302, 168–178 (2009).
20. Smith, N. L. et al. Association of genome-wide variation with the risk of
incident heart failure in adults of European and African ancestry: a prospective
meta-analysis from the cohorts for heart and aging research in genomic
epidemiology (CHARGE) consortium. Circ. Cardiovasc. Genet. 3, 256–266
(2010).
21. Dupuis, J. et al. New genetic loci implicated in fasting glucose homeostasis and
their impact on type 2 diabetes risk. Nat. Genet. 42, 105–116 (2010).
22. Morris, A. P. Transethnic meta-analysis of genomewide association studies.
Genet. Epidemiol. 35, 809–822 (2011).
23. Pers, T. H. et al. Biological interpretation of genome-wide association studies
using predicted gene functions. Nat. Commun. 6, 5890 (2015).
24. Trynka, G. et al. Chromatin marks identify critical cell types for ﬁne mapping
complex trait variants. Nat. Genet. 45, 124–130 (2013).
25. Raychaudhuri, S. et al. Identifying relationships among genomic disease
regions: predicting genes at pathogenic SNP associations and rare deletions.
PLoS Genet. 5, e1000534 (2009).
26. Panagiotou, O. A., Willer, C. J., Hirschhorn, J. N. & Ioannidis, J. P. The power
of meta-analysis in genome-wide association studies. Annu. Rev. Genomics
Hum. Genet. 14, 441–465 (2013).
27. Barker, D. J. The fetal and infant origins of adult disease. BMJ 301, 1111
(1990).
28. Boubred, F. et al. Developmental origins of chronic renal disease: an integrative
hypothesis. Int. J. Nephrol. 2013, 346067 (2013).
29. Fox, C. S. et al. Predictors of new-onset kidney disease in a community-based
population. JAMA 291, 844–850 (2004).
30. Coresh, J. et al. Calibration and random variation of the serum creatinine assay
as critical elements of using equations to estimate glomerular ﬁltration rate.
Am. J. Kidney Dis. 39, 920–929 (2002).
31. Stevens, L. A. et al. Estimating GFR using serum cystatin C alone and in
combination with serum creatinine: a pooled analysis of 3,418 individuals with
CKD. Am. J. Kidney Dis. 51, 395–406 (2008).
32. Fuchsberger, C., Taliun, D., Pramstaller, P. P. & Pattaro, C. CKDGen
consortium. GWAtoolbox: an R package for fast quality control
and handling of GWAS meta-analysis data. Bioinformatics 28, 444–445
(2012).
33. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efﬁcient meta-analysis of
genomewide association scans. Bioinformatics 26, 2190–2191 (2010).
34. Devlin, B. & Roeder, K. Genomic control for association studies. Biometrics 55,
997–1004 (1999).
35. Skol, A. D., Scott, L. J., Abecasis, G. R. & Boehnke, M. Joint analysis is more
efﬁcient than replication-based analysis for two-stage genome-wide association
studies. Nat. Genet. 38, 209–213 (2006).
36. Storey, J. D. A direct approach to false discovery rates. J. R. Stat. Soc. B 64,
479–498 (2002).
37. Storey, J. D., Taylor, J. E. & Siegmund, D. Strong control, conservative point
estimation, and simultaneous conservative consistency of false discovery rates: a
uniﬁed approach. J. R. Stat. Soc. B 66, 187–205 (2004).
38. Gauderman, W. J. Sample size requirements for matched case-control studies of
gene-environment interaction. Stat. Med. 21, 35–50 (2002).
39. Rosner, B. in Fundamentals of Biostatistics (Thomson-Brooks/Cole, Duxbury,
2006).
40. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait
associations. Nucleic Acids Res. 42, D1001–D1006 (2014).
41. Wang, X. et al. Comparing methods for performing trans-ethnic meta-analysis
of genome-wide association studies. Hum. Mol. Genet. 22, 2303–2311 (2013).
42. Purcell, S. et al. PLINK: a tool set for whole-genome association and
population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
43. International HapMap Consortium. The International HapMap Project. Nature
426, 789–796 (2003).
44. Maurano, M. T. et al. Systematic localization of common disease-associated
variation in regulatory DNA. Science 337, 1190–1195 (2012).
45. ENCODE Project Consortium et al. An integrated encyclopedia of DNA
elements in the human genome. Nature 489, 57–74 (2012).
46. Ko, Y. A. et al. Cytosine methylation changes in enhancer regions of core pro-
ﬁbrotic genes characterize kidney ﬁbrosis development. Genome Biol. 14, R108
(2013).
47. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9,
R137 (2008).
48. Shannon, P. et al. Cytoscape: a software environment for integrated models of
biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
Acknowledgements
Study-speciﬁc acknowledgements and funding sources for participating studies are
reported in Supplementary Note. Zebraﬁsh work was supported by NIH R01DK090311
and R24OD017870 to W.G.
Author contributions
Study design: C Helmer, B Stengel, J Chalmers, M Woodward, P Hamet, G Eiriksdottir,
LJ Launer, TB Harris, V Gudnason, JR O’Connell, A Ko¨ttgen, E Boerwinkle, WHL Kao,
P Mitchell, I Guessous, JM Gaspoz, N Bouatia-Naji, P Froguel, A Metspalu, T Esko,
BA Oostra, CM van Duijn, V Emilsson, H Brenner, I Borecki, CS Fox, Q Yang,
BK Kra¨mer, PS Wild, BI Freedman, J Ding, Y Liu, AB Zonderman, MK Evans,
A Adeyemo, CN Rotimi, D Cusi, P Gasparini, M Ciullo, D Toniolo, C Gieger,
C Meisinger, CA Bo¨ger, HE Wichmann, T Illig, I Rudan, W Ma¨rz, PP Pramstaller,
EP Bottinger, BW Penninx, H Snieder, U Gyllensten, AF Wright, H Campbell, JF Wilson,
SH Wild, GJ Navis, BM Buckley, I Ford, JW Jukema, B Paulweber, L Kedenko,
F Kronenberg, K Endlich, R Rettig, R Biffar, H Vo¨lzke, JK Fernandes, MM Sale,
M Pruijm, GB Ehret, A To¨njes, M Stumvoll, JC Denny, RJ Carroll, N Hastie, O Polasek,
PM Ridker, J Viikari, M Ka¨ho¨nen, O Raitakari, T Lehtima¨ki.
Study management: C Helmer, M Metzger, J Tremblay, J Chalmers, M Woodward,
P Hamet, G Eiriksdottir, TB Harris, T Aspelund, V Gudnason, A Parsa, AR Shuldiner,
BD Mitchell, E Boerwinkle, J Coresh, WHL Kao, R Schmidt, L Ferrucci, E Rochtchina,
JJ Wang, J Attia, P Mitchell, I Guessous, JM Gaspoz, M Bochud, DS Siscovick, O Devuyst,
P Froguel, T Esko, BA Oostra, CM van Duijn, V Emilsson, AK Dieffenbach, H Brenner,
I Borecki, CS Fox, M Rheinberger, ST Turner, S Kloiber, PS Wild, J Ding, Y Liu,
SLR Kardia, AB Zonderman, MK Evans, MC Cornelis, A Adeyemo, CN Rotimi, D Cusi,
E Salvi, PB Munroe, P Gasparini, M Ciullo, R Sorice, C Sala, D Toniolo, AW Dreisbach,
DI Chasman, C Gieger, C Meisinger, M Waldenberger, HE Wichmann, T Illig,
W Koenig, I Rudan, I Kolcic, M Boban, T Zemunik, W Ma¨rz, H Kramer, PP Pramstaller,
EP Bottinger, O Gottesman, BW Penninx, H Snieder, JH Smit, AF Wright, H Campbell,
JF Wilson, SH Wild, W Lieb, GJ Navis, BM Buckley, I Ford, JW Jukema, A Hofman,
OH Franco, M Adam, M Imboden, N Probst-Hensch, B Paulweber, L Kedenko,
F Kronenberg, S Coassin, M Haun, HK Kroemer, K Endlich, M Nauck, R Rettig,
R Biffar, S Stracke, U Vo¨lker, H Wallaschofski, H Vo¨lzke, KL Keene, MM Sale, B Ponte,
D Ackermann, M Pruijm, GB Ehret, A To¨njes, P Kovacs, JC Denny, RJ Carroll,
C Hayward, O Polasek, V Vitart, PM Ridker, J Viikari, M Ka¨ho¨nen, O Raitakari,
T Lehtima¨ki.
Subject recruitment: C Helmer, P Hamet, TB Harris, T Aspelund, V Gudnason,
AR Shuldiner, BD Mitchell, J Coresh, WHL Kao, M Cavalieri, R Schmidt, JB Whitﬁeld,
NG Martin, L Ferrucci, P Mitchell, I Guessous, DS Siscovick, O Devuyst, A Metspalu,
BA Oostra, CM van Duijn, BK Kra¨mer, ST Turner, S Kloiber, PS Wild, BI Freedman,
MA McEvoy, RJ Scott, AB Zonderman, MK Evans, GC Curhan, A Adeyemo, CN Rotimi,
D Cusi, A Lupo, G Gambaro, P d’Adamo, A Robino, S Ulivi, D Ruggiero, M Ciullo,
R Sorice, D Toniolo, C Gieger, C Meisinger, CA Bo¨ger, HE Wichmann, T Illig,
W Koenig, I Rudan, I Kolcic, M Boban, T Zemunik, PP Pramstaller, EP Bottinger,
BW Penninx, Å Johansson, I Persico, M Pirastu, JF Wilson, SH Wild, A Franke, G Jacobs,
GJ Navis, IM Leach, BM Buckley, I Ford, JW Jukema, N Probst-Hensch, B Paulweber,
L Kedenko, F Kronenberg, R Rettig, R Biffar, S Stracke, H Vo¨lzke, P Muntner,
JK Fernandes, MM Sale, B Ponte, D Ackermann, M Pruijm, GB Ehret, A To¨njes,
JC Denny, RJ Carroll, O Polasek, J Viikari, M Ka¨ho¨nen, O Raitakari, T Lehtima¨ki.
Interpretation of results: C Helmer, JC Lambert, M Metzger, B Stengel, V Chouraki,
J Tremblay, J Chalmers, M Woodward, P Hamet, AV Smith, A Parsa, JR O’Connell,
A Tin, A Ko¨ttgen, M Li, WHL Kao, Y Li, EG Holliday, J Attia, I Guessous, CA Peralta,
AC Morrison, JF Felix, C Pattaro, G Li, IH de Boer, O Devuyst, H Lin, A Isaacs,
V Emilsson, AD Johnson, CS Fox, M Olden, Q Yang, EJ Atkinson, M de Andrade,
ST Turner, T Zeller, J Ding, Y Liu, M Nalls, A Adeyemo, D Shriner, D Cusi, E Salvi,
V Mijatovic, D Ruggiero, R Sorice, AW Dreisbach, AY Chu, DI Chasman, CA Bo¨ger,
IM Heid, M Gorski, B Tayo, C Fuchsberger, H Snieder, IM Nolte, W Igl, K Susztak,
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10023
10 NATURE COMMUNICATIONS | 7:10023 | DOI: 10.1038/ncomms10023 | www.nature.com/naturecommunications
N Verweij, S Trompet, A Dehghan, B Kollerits, F Kronenberg, A Teumer, J Divers,
KL Keene, MM Sale, WM Chen, GB Ehret, I Prokopenko, R Ma¨gi, JC Denny, RJ Carroll.
Design, performance and interpretation of zebraﬁsh experiments: M Garnaas,
W Goessling.
Drafting manuscript: J Chalmers, A Tin, A Ko¨ttgen, WHL Kao, M Bochud, CA Peralta,
C Pattaro, IH de Boer, CS Fox, M Garnaas, W Goessling, N Soranzo, CA Bo¨ger, IM Heid,
M Gorski, S Trompet, A Dehghan, A Teumer, KL Keene, MM Sale.
Critical review of the manuscript: J Tremblay, J Chalmers, M Woodward, P Hamet,
TB Harris, V Gudnason, A Parsa, AR Shuldiner, BD Mitchell, A Tin, A Ko¨ttgen,
E Boerwinkle, J Coresh, M Li, WHL Kao, Y Li, H Schmidt, M Cavalieri, R Schmidt,
JB Whitﬁeld, EG Holliday, JJ Wang, J Attia, P Mitchell, I Guessous, JM Gaspoz,
M Bochud, CA Peralta, AC Morrison, JF Felix, C Pattaro, DS Siscovick, IH de Boer,
M Rao, R Katz, O Devuyst, TH Pers, A Isaacs, H Brenner, M Garnaas, W Goessling,
BK Kra¨mer, M Rheinberger, ST Turner, D Czamara, S Kloiber, T Zeller, BI Freedman,
JM Stafford, J Ding, Y Liu, MA McEvoy, RJ Scott, SJ Hancock, JA Smith, JD Faul,
SLR Kardia, AB Zonderman, M Nalls, MK Evans, FB Hu, GC Curhan, MC Cornelis,
A Lupo, G Gambaro, G Malerba, M Ciullo, R Sorice, AW Dreisbach, AY Chu,
DI Chasman, C Gieger, H Grallert, C Meisinger, M Waldenberger, CA Bo¨ger,
HE Wichmann, IM Heid, M Gorski, T Illig, W Koenig, I Kolcic, M Boban, T Zemunik,
W Ma¨rz, B Tayo, H Kramer, SE Rosas, C Fuchsberger, D Ruderfer, EP Bottinger,
O Gottesman, RJF Loos, Y Lu, H Snieder, H Campbell, A Franke, W Lieb, IM Leach,
BM Buckley, I Ford, JW Jukema, S Trompet, A Dehghan, S Sedaghat, GA Thun,
M Adam, M Imboden, N Probst-Hensch, B Kollerits, B Paulweber, L Kedenko,
F Kronenberg, A Teumer, K Endlich, H Vo¨lzke, KL Keene, MM Sale, WM Chen,
B Ponte, D Ackermann, M Pruijm, GB Ehret, A To¨njes, I Prokopenko, M Stumvoll,
P Kovacs, R Ma¨gi, JC Denny, O Polasek, J Viikari, LP Lyytika¨inen, M Ka¨ho¨nen,
O Raitakari, T Lehtima¨ki.
Statistical methods and analysis: C Helmer, JC Lambert, M Metzger, V Chouraki,
J Tremblay, P Hamet, AV Smith, T Aspelund, A Parsa, JR O’Connell, A Tin, A Ko¨ttgen,
M Li, M Foster, WHL Kao, Y Li, H Schmidt, M Struchalin, NG Martin, RPS Middelberg,
T Tanaka, E Rochtchina, EG Holliday, I Guessous, M Bochud, JF Felix, C Pattaro, G Li,
R Katz, JN Hirschhorn, J Karjalainen, L Franke, TH Pers, L Yengo, N Bouatia-Naji,
H Lin, T Nikopensius, T Esko, A Isaacs, A Demirkan, MF Feitosa, M Olden, MH Chen,
Q Yang, SJ Hwang, M Garnaas, W Goessling, EJ Atkinson, M de Andrade, D Czamara,
S Kloiber, C Mu¨ller, JM Stafford, J Ding, K Lohman, Y Liu, JA Smith, JD Faul, M Nalls,
MC Cornelis, A Adeyemo, D Shriner, E Salvi, V Mijatovic, A Robino, S Ulivi, R Sorice,
G Pistis, M Cocca, AY Chu, DI Chasman, LM Rose, CA Bo¨ger, IM Heid, M Gorski,
ME Kleber, B Tayo, C Fuchsberger, A Saint-Pierre, D Taliun, D Ruderfer, Y Lu,
IM Nolte, PJ van der Most, S Enroth, W Igl, F Murgia, L Portas, K Susztak, YA Ko,
N Verweij, S Trompet, A Dehghan, S Sedaghat, GA Thun, M Adam, M Imboden,
N Probst-Hensch, B Kollerits, A Teumer, J Divers, WM Chen, GB Ehret, I Prokopenko,
R Ma¨gi, CM Shaffer, RJ Carroll, C Hayward, V Vitart, LP Lyytika¨inen, V Aalto.
Genotyping: JC Lambert, J Tremblay, P Hamet, E Boerwinkle, WHL Kao,
H Schmidt, GW Montgomery, L Ferrucci, M Bochud, BA Oostra, CM van Duijn,
K Butterbach, I Borecki, M de Andrade, T Zeller, Y Liu, RJ Scott, SLR Kardia,
M Nalls, FB Hu, GC Curhan, A Adeyemo, D Shriner, D Cusi, N Soranzo, P d’Adamo,
D Ruggiero, M Ciullo, R Sorice, DI Chasman, H Grallert, T Zemunik, ME Kleber,
EP Bottinger, O Gottesman, RJF Loos, AF Wright, JF Wilson, A Franke, D Ellinghaus,
JW Jukema, S Trompet, AG Uitterlinden, F Rivadeneira, F Kronenberg, S Coassin,
M Haun, F Ernst, G Homuth, HK Kroemer, M Nauck, U Vo¨lker, H Wallaschofski,
MM Sale, GB Ehret, A To¨njes, M Stumvoll, P Kovacs, CM Shaffer, JC Denny, PM Ridker,
T Lehtima¨ki.
Bioinformatics: JC Lambert, V Chouraki, J Tremblay, P Hamet, AV Smith, T Aspelund,
JR O’Connell, E Boerwinkle, Y Li, M Struchalin, GW Montgomery, RPS Middelberg,
T Tanaka, C Pattaro, G Li, JN Hirschhorn, J Karjalainen, L Franke, TH Pers, L Yengo,
T Esko, AD Johnson, M Olden, M Garnaas, W Goessling, D Czamara, C Mu¨ller,
JA Smith, SLR Kardia, M Nalls, E Salvi, G Malerba, V Mijatovic, P d’Adamo, S Ulivi,
R Sorice, C Sala, G Pistis, M Cocca, DI Chasman, H Grallert, M Waldenberger,
CA Bo¨ger, IM Heid, M Gorski, ME Kleber, D Taliun, O Gottesman, S Enroth, K Susztak,
YA Ko, D Ellinghaus, N Verweij, I Ford, S Trompet, F Rivadeneira, WM Chen, GB Ehret,
R Ma¨gi, CM Shaffer, JC Denny, RJ Carroll, C Hayward, LP Lyytika¨inen, V Aalto.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: J.T. and P.H. are consultants for Servier. J.C. received
research grants and honoraria from Servier. K.S. obtained research support from
Boehringer Ingelheim. The remaining authors declared no competing ﬁnancial
interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Pattaro, C. et al. Genetic associations at 53 loci highlight cell
types and biological pathways relevant for kidney function. Nat. Commun. 7:10023
doi: 10.1038/ncomms10023 (2016).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Cristian Pattaro1,*, Alexander Teumer2,3,*, Mathias Gorski4,5,*, Audrey Y. Chu6,*, Man Li7,*, Vladan Mijatovic8,*,
Maija Garnaas9, Adrienne Tin7, Rossella Sorice10, Yong Li11, Daniel Taliun1, Matthias Olden4,5, Meredith Foster12,
Qiong Yang13, Ming-Huei Chen13,14, Tune H. Pers15,16, Andrew D. Johnson17, Yi-An Ko18, Christian Fuchsberger1,
Bamidele Tayo19, Michael Nalls20, Mary F. Feitosa21, Aaron Isaacs22,23, Abbas Dehghan24, Pio d’Adamo25,
Adebowale Adeyemo26, Aida Karina Dieffenbach27,28, Alan B. Zonderman29, Ilja M. Nolte30, Peter J. van der
Most30, Alan F. Wright31, Alan R. Shuldiner32,33, Alanna C. Morrison34, Albert Hofman24, Albert V. Smith35,36,
Albert W. Dreisbach37, Andre Franke38, Andre G. Uitterlinden39, Andres Metspalu40,41, Anke Tonjes42,
Antonio Lupo43, Antonietta Robino25, Åsa Johansson44, Ayse Demirkan22, Barbara Kollerits45,
Barry I. Freedman46, Belen Ponte47, Ben A. Oostra48, Bernhard Paulweber49, Bernhard K. Kra¨mer50,
Braxton D. Mitchell32,33, Brendan M. Buckley51, Carmen A. Peralta52, Caroline Hayward31, Catherine Helmer53,54,
Charles N. Rotimi26, Christian M. Shaffer55, Christian Mu¨ller56,57, Cinzia Sala58, Cornelia M. van Duijn22,
Aude Saint-Pierre1,59, Daniel Ackermann47, Daniel Shriner26, Daniela Ruggiero10, Daniela Toniolo58,60,
Yingchang Lu61, Daniele Cusi62, Darina Czamara63, David Ellinghaus38, David S. Siscovick64,
Douglas Ruderfer65, Christian Gieger66, Harald Grallert67,68,69, Elena Rochtchina70, Elizabeth J. Atkinson71,
Elizabeth G. Holliday72,73, Eric Boerwinkle34, Erika Salvi62, Erwin P. Bottinger61, Federico Murgia74,
Fernando Rivadeneira39, Florian Ernst2, Florian Kronenberg45, Frank B. Hu75, Gerjan J. Navis76, Gary C. Curhan77,
George B. Ehret78, Georg Homuth2, Stefan Coassin45, Gian-Andri Thun79,80, Giorgio Pistis58,
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10023 ARTICLE
NATURE COMMUNICATIONS | 7:10023 | DOI: 10.1038/ncomms10023 | www.nature.com/naturecommunications 11
Giovanni Gambaro81, Giovanni Malerba8, Grant W. Montgomery82, Gudny Eiriksdottir35, Gunnar Jacobs83,
Guo Li64, H-Erich Wichmann84,85,86, Harry Campbell87, Helena Schmidt88, Henri Wallaschofski89,90, Henry
Vo¨lzke3,90, Hermann Brenner27,28, Heyo K. Kroemer91, Holly Kramer19, Honghuang Lin92,
I. Mateo Leach93, Ian Ford94, Idris Guessous95,96,97, Igor Rudan87, Inga Prokopenko98, Ingrid Borecki21,
Iris M. Heid4,66, Ivana Kolcic99, Ivana Persico74, J. Wouter Jukema100,101,102,103, James F. Wilson87,
Janine F. Felix24, Jasmin Divers104, Jean-Charles Lambert105, Jeanette M. Stafford104, Jean-Michel Gaspoz95,
Jennifer A. Smith106, Jessica D. Faul107, Jie Jin Wang108, Jingzhong Ding109, Joel N. Hirschhorn15,16,110,
John Attia71,72, John B. Whitﬁeld82, John Chalmers111, Jorma Viikari112, Josef Coresh7,113, Joshua C. Denny114,
Juha Karjalainen115, Jyotika K. Fernandes116, Karlhans Endlich117, Katja Butterbach27, Keith L. Keene118,
Kurt Lohman46, Laura Portas74, Lenore J. Launer119, Leo-Pekka Lyytika¨inen120, Loic Yengo121,122,123,
Lude Franke115, Luigi Ferrucci124, Lynda M. Rose6, Lyudmyla Kedenko49, Madhumathi Rao12,
Maksim Struchalin125,126, Marcus E. Kleber127, Margherita Cavalieri128, Margot Haun45, Marilyn C. Cornelis75,
Marina Ciullo10, Mario Pirastu74, Mariza de Andrade71, Mark A. McEvoy129, Mark Woodward7,111,112,130,
Martin Adam79,80, Massimiliano Cocca58, Matthias Nauck89,90, Medea Imboden79,80, Melanie Waldenberger67,
Menno Pruijm131, Marie Metzger132, Michael Stumvoll42, Michele K. Evans133, Michele M. Sale134,
Mika Ka¨ho¨nen135, Mladen Boban99, Murielle Bochud136, Myriam Rheinberger5, Niek Verweij93,
Nabila Bouatia-Naji137,138, Nicholas G. Martin82,139, Nick Hastie31, Nicole Probst-Hensch79,80, Nicole Soranzo140,
Olivier Devuyst141, Olli Raitakari142, Omri Gottesman61, Oscar H. Franco24, Ozren Polasek99, Paolo Gasparini25,
Patricia B. Munroe143,144, Paul M. Ridker145, Paul Mitchell108, Paul Muntner146,147, Christa Meisinger68,
Johannes H. Smit148, ICBP Consortiumw, AGEN Consortiumw, CARDIOGRAMw, CHARGe-Heart Failure Groupw,
ECHOGen Consortiumw, Peter Kovacs149, Philipp S. Wild150, Philippe Froguel121,122,123, Rainer Rettig151,
Reedik Ma¨gi40, Reiner Biffar152, Reinhold Schmidt128, Rita P.S. Middelberg82, Robert J. Carroll114,
Brenda W. Penninx148, Rodney J. Scott153, Ronit Katz154, Sanaz Sedaghat24, Sarah H. Wild87,
Sharon L.R. Kardia106, Sheila Ulivi155, Shih-Jen Hwang17, Stefan Enroth44, Stefan Kloiber63, Stella Trompet100,
Benedicte Stengel132, Stephen J. Hancock72,73, Stephen T. Turner156, Sylvia E. Rosas18, Sylvia Stracke105,157,
Tamara B. Harris119, Tanja Zeller56,57, Tatijana Zemunik99, Terho Lehtima¨ki120, Thomas Illig68,
Thor Aspelund35,36, Tiit Nikopensius40,41, Tonu Esko15,40,41, Toshiko Tanaka124, Ulf Gyllensten44, Uwe Vo¨lker2,90,
Valur Emilsson35,158, Veronique Vitart31, Ville Aalto159, Vilmundur Gudnason35,36, Vincent Chouraki105,
Wei-Min Chen134, Wilmar Igl44, Winfried Ma¨rz160, Wolfgang Koenig161, Wolfgang Lieb83, Ruth J.F. Loos61,162,
Yongmei Liu46, Harold Snieder30, Peter P. Pramstaller1,163,164, Afshin Parsa165, Jeffrey R. O’Connell32,
Katalin Susztak18, Pavel Hamet166, Johanne Tremblay166, Ian H. de Boer154, Carsten A. Bo¨ger5,**,
Wolfram Goessling9,**, Daniel I. Chasman6,145,**, Anna Ko¨ttgen7,11,**, W.H. Linda Kao7,113,**,z
& Caroline S. Fox17,167,**
1 Center for Biomedicine, European Academy of Bozen/Bolzano (EURAC), afﬁliated to the University of Lu¨beck, Via Galvani 31, Bolzano 39100, Italy.
2 Interfaculty Institute for Genetics and Functional Genomics, Ernst-Moritz-Arndt-University Greifswald, Friedrich-Loefﬂer-Strae 15a, Greifswald 17487,
Germany. 3 Institute for Community Medicine, University of Greifswald, Walther-Rathenau-Strasse 48, Greifswald 17487, Germany. 4Department of Genetic
Epidemiology, Institute of Epidemiology and Preventive Medicine, University of Regensburg, Franz-Josef-Strau-Allee 11, Regensburg 93053, Germany.
5 Department of Nephrology, University Hospital Regensburg, Franz-Josef-Strau-Allee 11, Regensburg 93053, Germany. 6 Preventive Medicine, Brigham and
Women’s Hospital, 900 Commonwealth Avenue East, Boston, Massachusetts 02215, USA. 7Department of Epidemiology, Johns Hopkins Bloomberg School
of Public Health, 615 North Wolfe Street, Baltimore, Maryland 21205, USA. 8Department of Life and Reproduction Sciences, University of Verona, Strada Le
Grazie 8, Verona 37134, Italy. 9 Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, New Research
Building77 Avenue Louis Pasteur, Room 458, Boston, Massachusetts 02115, USA. 10 Institute of Genetics and Biophysics "Adriano Buzzati-Traverso"—CNR,
Via P. Castellino 111, Napoli 80131, Italy. 11 Department of Internal Medicine IV, University Hospital Freiburg, Berliner Allee 29, Freiburg 79110, Germany.
12 Division of Nephrology/Tufts Evidence Practice Center, Tufts University School of Medicine, Tufts Medical Center, Boston, Massachusetts 02111, USA.
13 Department of Biostatistics, Boston University School of Public Health, 715 Albany Street, Boston, Massachusetts 02118, USA. 14 Department of Neurology,
Boston University School of Medicine, 72 East Concord ST B603, Boston, Massachusetts 02118, USA. 15 Division of Endocrinology and Center for Basic and
Translational Obesity Research, Boston Children’s Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, USA. 16Medical and Population Genetics
Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 2142, USA. 17 NHLBI’s Framingham Heart Study and the Center for Population
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10023
12 NATURE COMMUNICATIONS | 7:10023 | DOI: 10.1038/ncomms10023 | www.nature.com/naturecommunications
Studies, 73 Mt Wayte Avenue, Suite 2, Framingham, Massachusetts 01702, USA. 18 Renal Electrolyte and Hypertension Division, Perelman School of
Medicine, University of Pennsylvania, 415 Curie Boulevard, 405B Clinical Research Building, Philadelphia, Pennsylvania 19104-4539, USA. 19 Department of
Public Health Sciences, Loyola Medical Center, 2160 S First Avenue, Maywood, Illinois 60153, USA. 20 Laboratory of Neurogenetics, Building 35—Porter
Building, 1A1015, National Institute on Aging/NIH, Bethesda, Maryland 20892, USA. 21 Division of Statistical Genomics, Washington University School of
Medicine, 4444 Forest Park Boulevard, Box 8506, St Louis, Missouri 63108, USA. 22 Genetic Epidemiology Unit, Department of Epidemiology, Erasmus
University Medical Center, Dr Molewaterplein 50, PO Box 2040, Rotterdam 3000 CA, The Netherlands. 23 Centre for Medical Systems Biology Leiden,
Dr Molewaterplein 50, PO Box 2040, Rotterdam 3000 CA, The Netherlands. 24Department of Epidemiology, Erasmus University Medical Center, PO Box
2040, Rotterdam 3000 CA, The Netherlands. 25 Institute for Maternal and Child Health—IRCCS "Burlo Garofolo" and University of Trieste, via dell’Istria 65/1,
Trieste 34137, Italy. 26 Center for Research on Genomics and Global Health, National Human Genome Research Institute, Building 12A, Room 4047, 12 South
Dr, MSC 5635, Bethesda, Maryland 20892-5635, USA. 27 Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ),
Im Neuenheimer Feld 581, Heidelberg 69120, Germany. 28 German Cancer Consortium (DKTK), Im Neuenheimer Feld 581, Heidelberg 69120, Germany.
29 Laboratory of Personality and Cognition, National Institute on Aging, National Institutes of Health, NIH Biomedical Center, 251 Bayview Boulevard, Suite
100, Baltimore, Maryland 21224, USA. 30 Unit of Genetic Epidemiology and Bioinformatics, Department of Epidemiology, University Medical Center
Groningen, PO Box 30001, Groningen 9700 RB, The Netherlands. 31MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of
Edinburgh, Crewe Road, Edinburgh EH4 2XU, UK. 32 Department of Medicine, University of Maryland School of Medicine, 685 West Baltimore Street,
Baltimore, Maryland 21201, USA. 33 Geriatric Research and Education Clinical Center, Veterans Administration Medical Center, 10 North Greene Street,
Baltimore, Maryland 21201, USA. 34Human Genetics Center, University of Texas Health Science Center at Houston, 1200 Pressler St Suite 453E, Houston,
Texas 77030, USA. 35 Icelandic Heart Association, Research Institute, Holtasmari 1, Kopavogur 201, Iceland. 36 University of Iceland, Sæmundargo¨tu 2,
Reykjavik 101, Iceland. 37 Division of Nephrology, University of Mississippi, 2500 North State Street, Jackson, Mississippi 39216, USA. 38 Institute of Clinical
Molecular Biology, Christian-Albrechts University of Kiel, Schittenhelmstrae 12, Kiel 24105, Germany. 39Department of Internal Medicine, Erasmus
University Medical Center, PO Box 1738, Rotterdam 3000 DR, The Netherlands. 40 Estonian Genome Center of University of Tartu (EGCUT), Riia 23B, Tartu
51010, Estonia. 41 Institute of Molecular and Cell Biology, University of Tartu and Estonian Biocenter, Riia 23, Tartu 51010, Estonia. 42 Department of Medicine,
University of Leipzig, Liebigstrae 18, Leipzig 04103, Germany. 43 Division of Nephrology, Department of Medicine, University of Verona, Piazzale Aristide
Stefani 1, Verona 37126, Italy. 44 Uppsala University, Department of Immunology, Genetics and Pathology, Biomedical Center, SciLifeLab, Uppsala University,
Uppsala SE- 75108, Sweden. 45 Innsbruck Medical University, Division of Genetic Epidemiology, Schoepfstrae 41, Innsbruck 6020, Austria. 46 Internal
Medicine Department, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina 27157-1053, USA. 47Nephrology
Division, Department of Specialties of Internal Medicine, Geneva University Hospital, 4 rue Gabrielle-Perret-Gentil, Geneve 1211, Switzerland. 48Department
of Clinical Genetics, Erasmus University Medical Center, Dr Molewaterplein 50, PO Box 2040, Rotterdam 3000 CA, The Netherlands. 49 First Department of
Internal Medicine, Paracelsus Medical University/Salzburger Landeskliniken, Mu¨llner Hauptstrae 48, Salzburg 5020, Austria. 50 University Medical Centre
Mannheim, 5th Department of Medicine, University of Heidelberg, Theodor Kutzer Ufer 1-3, Mannheim 68167, Germany. 51 Department of Pharmacology and
Therapeutics, University College Cork, Clinical Investigations Building, Western Rd, Cork, Ireland. 52 Division of Nephrology, University of California, San
Francisco Medical School and San Francisco VA Medical Center, 4150 Clement Street, San Francisco, California 94121, USA. 53 INSERM, ISPED, Centre
INSERM U897—Epidemiologie-Biostatistique, Bordeaux F-33000, France. 54Universite´ Bordeaux, ISPED, Centre INSERM U897-Epidemiologie-
Biostatistique, Bordeaux F-33000, France. 55 Vanderbilt University School of Medicine, 2215-B Garland Avenue 1224—MRB4 (Light Hall)Nashville, Tennessee
37232, USA. 56University Heart Center Hamburg, Clinic for general and interventional cardiology, Martinistrae 52, Hamburg 20246, Germany. 57 German
Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Lu¨beck/Kiel, Martinistrae 52, Hamburg 20246, Germany. 58Division of Genetics and
Cell Biology, San Raffaele Scientiﬁc Institute, Via Olgettina 58, Milano 20132, Italy. 59 INSERM U1078, Etablissement Franc¸ais du Sang, 46 rue Fe´lix Le
Dantec, CS 51819, Brest Cedex 2 29218, France. 60 Institute of Molecular Genetics-CNR, Via Abbiategrasso 207, Pavia 27100, Italy. 61 The Charles Bronfman
Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA. 62Department of Health Sciences, University
of Milano, Via Antonio di Rudinı` 8, Milano 20142, Italy. 63Max Planck Institute of Psychiatry, Kraepelinstrae 2–10, Munich 80804, Germany.
64 Cardiovascular Health Research Unit, Departments of Epidemiology and Medicine, University of Washington, 1730 Minor Ave, Suite 1360, Seattle,
Washington 98101, USA. 65Division of Psychiatric Genomics, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York
10029, USA. 66 Institute of Genetic Epidemiology, Helmholtz Zentrum Mu¨nchen, German Research Center for Environmental Health, Ingolstaedter
Landstrae 1, 85764 Neuherberg, Germany. 67 Research Unit of Molecular Epidemiology, Helmholtz Zentrum Mu¨nchen, German Research Center for
Environmental Health, Ingolstaedter Landstrae 1, 85764 Neuherberg, Germany. 68 Institute of Epidemiology II, Helmholtz Zentrum Mu¨nchen, German
Research Center for Environmental Health, 85764 Neuherberg, Germany. 69 German Center for Diabetes Research (DZD), Ingolstaedter Landstrae 1,
Neuherberg 85764, Germany. 70Westmead Millennium Institute, Centre for Vision Research, University of Sydney, C24 Westmead Hospital, New South
Wales 2145, Australia. 71 Division of Biomedical Statistics and Informatics, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA. 72 Centre for
Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, University of Newcastle, HMRI Building1, Kookaburra Circuit, New Lambton
New South Wales 2305, Australia. 73 Clinical Research Design, Information Technology and Statistical Support, Hunter Medical Research Institute,
Newcastle, 1 Kookaburra Circuit, New Lambton Heights, New South Wales 2305, Australia. 74 Institute of Population Genetics—CNR, Traversa La Crucca 3,
07040 Reg. Baldinca, Li Punti, Sassari, Italy. 75 Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Building 2, Boston,
Massachusetts 02115, USA. 76Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen 9713
GZ, The Netherlands. 77 Brigham and Women’s Hospital and Channing Laboratory, Harvard Medical School, 181 Longwood Avenue, Boston, Massachusetts
02115, USA. 78 Cardiology, Department of Specialties of Internal Medicine, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, Geneva 1205,
Switzerland. 79 Swiss Tropical and Public Health Institute, PO Box 4002, Basel, Switzerland. 80 University of Basel, Petersplatz 1, Basel 4003, Switzerland.
81 Division of Nephrology, Department of Internal Medicine and Medical Specialties, Columbus-Gemelli University Hospital, Catholic University, Via Moscati
31, Rome 00168, Italy. 82 Genetic Epidemiology, Queensland Institute of Medical Research, QIMR, PO Royal Brisbane Hospital, Queensland 4029, Australia.
83 Institute of Epidemiology and Biobank popgen, Christian-Albrechts University, Niemannsweg 11, Kiel 24105, Germany. 84 Institute of Epidemiology I,
Helmholtz Zentrum Mu¨nchen, German Research Center for Environmental Health, Ingolsta¨dter Landstrae 1, Neuherberg 85764, Germany. 85 Institute of
Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universita¨t, Ingolsta¨dter Landstrasse 1, 85764 Neuherberg, Germany. 86 Klinikum
Grosshadern, Ingolsta¨dter Landstrae 1, Neuherberg 85764, Germany. 87 Centre for Population Health Sciences, University of Edinburgh, Teviot Place,
Edinburgh, EH8 9AG Scotland, UK. 88 Austrian Stroke Prevention Study, Institute of Molecular Biology and Biochemistry, Department of Neurology, Medical
University Graz, Harrachgasse 21, Graz 8010, Austria. 89 Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Ferdinand-
Sauerbruch-Strae, Greifswald 17475, Germany. 90 German Center for Cardiovascular Research (DZHK), Partner site Greifswald, Ferdinand-Sauerbruch-
Strae, Greifswald 17475, Germany. 91 Institute of Pharmacology, University of Greifswald, Friedrich-Loefﬂer-Strae 23d, Greifswald 17487, Germany.
92 Boston University School of Medicine, 72 East Concord Street, B-616, Boston, Massachusetts 02118, USA. 93Department of Cardiology, University Medical
Center Groningen, University of Groningen, PO Box 30.001, Groningen 9700 RB, The Netherlands. 94 Robertson Centre for Biostatistics, University of
Glasgow, R1122B Level 11, Robertson Centre, Boyd Orr Building, Glasgow G12 8QQ, UK. 95Division of Primary Care Medicine, Department of Community
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10023 ARTICLE
NATURE COMMUNICATIONS | 7:10023 | DOI: 10.1038/ncomms10023 | www.nature.com/naturecommunications 13
Medicine, Primary Care and Emergency Medicine, Geneva University Hospitals, Faculty of Medicine, University of Geneva, Geneva 1211, Switzerland.
96 Community Prevention Unit, University Institute of Social and Preventive Medicine, Lausanne University Hospital, Route de la Corniche 10, Lausanne 1010,
Switzerland. 97 Department of Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road, NE, Atlanta, Georgia 30322, USA.
98Department of Genomics of Common Disease, School of Public Health, Imperial College London, London W12 0NN, UK. 99 Croatian Centre for Global
Health, University of Split Medical School, Sˇoltanska 2, Split 21000, Croatia. 100Department of Cardiology, Leiden University Medical Center, PO Box 9600,
Leiden 2300 RC, The Netherlands. 101 Interuniversity Cardiology Institute of the Netherlands (ICIN), Moreelsepark 1, Utrecht 3511 EP, The Netherlands.
102 Einthoven Laboratory for Experimental Vascular Medicine, Albinusdreef 2, Leiden 2333 ZA, The Netherlands. 103 Durrer Center for Cardiogenetic
Research, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands. 104Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest
University Health Sciences, 2326 Medical Center Boulevard, Winston-Salem, North Carolina 27157-1063, USA. 105 INSERM U744, Institut Pasteur de Lille, 1
rue du Pr, Calmette, Lille Ce´dex 59019, France. 106 Department of Epidemiology, School of Public Health, University of Michigan, 1415 Washington Heights,
Ann Arbor, Michigan 48109-2029, USA. 107 Survey Research Center, Institute for Social Research, University of Michigan, 426 Thompson Street, #3456, Ann
Arbor, Michigan 48104, USA. 108 Centre for Vision Research, Westmead Millennium Institute, University of Sydney, C24 Westmead Hospital, New South
Wales 2145, Australia. 109Wake Forest School of Medicine, Department of Internal Medicine/Geriatrics, Medical center Boulevard, Winston-Salem, North
Carolina 27157, USA. 110 Department of Genetics, Harvard Medical School, 77 Avenue Louis Pasteur, NRB 0330, Boston, Massachusetts 02115, USA.
111 University of Sydney, The George Institute for Global Health, Level 10, King George V Building, 83-117 Missenden Road, Camperdown, New South Wales
2050, Australia. 112 Department of Medicine, University of Turku, Turku University Hospital, PO Box 52, Turku 20521, Finland. 113Welch Center for Prevention,
Epidemiology and Clinical Research, 2024 East Monument St, Suite 2-600, Baltimore, Maryland 21287, USA. 114 Vanderbilt University School of Medicine,
448 Eskind Biomedical Library, 2209 Garland Avenue, Nashville, Tennessee 37212, USA. 115 Department of Genetics, University of Groningen, University
Medical Centre Groningen, PO Box 72, Groningen 9700 AB, The Netherlands. 116 Division of Endocrinology, Medical University of South Carolina, 171 Ashley
Avenue, Charleston, South Carolina 29425, USA. 117 Institute of Anatomy and Cell Biology, University of Greifswald, Friedrich-Loefﬂer-Strae 23c, Greifswald
17487, Germany. 118 Center for Health Disparities, Department of Biology, East Carolina University, 1001 East 10th Street, N209 Howell Science Complex
Mailstop 551, Greenville, North Carolina 27858, USA. 119 Intramural Research Program, Laboratory of Epidemiology, Demography, and Biometry, National
Institute on Aging, Gateway Building, 3C309, 7201 Winsconsin Avenue, Bethesda, Maryland 20892-9205, USA. 120Department of Clinical Chemistry,
Fimlab Laboratories, University of Tampere, School of Medicine, Tampere 33520, Finland. 121 CNRS UMR 8199, 1 Rue du Professeur Calmette, Lille 59000,
France. 122 Lille Pasteur Institute, 1 Rue du Professeur Calmette, Lille 59000, France. 123 Lille II University, 42 Rue paul Duez, Lille 59000, France. 124 Clinical
Research Branch, National Institute on Aging, 251 Bayview Blvd, Baltimore, Maryland 21250, USA. 125 Department of Epidemiology and Biostatistics, Erasmus
University Medical Center, Dr Molewaterplein, Rotterdam 50-603015 GE, The Netherlands. 126 Department of Forensic Molecular Biology, Erasmus
University Medical Center, Dr Molewaterplein, Rotterdam 50-603015 GE, The Netherlands. 127Medical Clinic V, Medical Faculty Mannheim, Heidelberg
University, Theodor-Kutzer-Ufer 1-3, Mannheim 68167, Germany. 128 Austrian Stroke Prevention Study, Department of Neurology, Division of Special
Neurology, Medical University Graz, Auenbruggerplatz 22, Graz 8036, Austria. 129 Centre for Clinical Epidemiology and Biostatistics, University of Newcastle,
Hunter Medical Research Institute, John Hunter Hospital, Locked Bag 1, HRMC, New South Wales 2310, Australia. 130 The George Institute for Global Health,
Nufﬁeld Department of Population Health, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, UK. 131 Service of Nephrology, Lausanne
University Hospital, Rue du Bugnon 17, Lausanne 1005, Switzerland. 132 Inserm UMRS 1018, CESP Team 10, Universite´ Paris-Sud, 16 avenue Paul Vaillant
Couturier, Villejuif 94807, France. 133 Health Disparities Research Section, Clinical Research Branch, National Institute on Aging, National Institutes of Health,
NIH Biomedical Center, 251 Bayview Boulevard, Suite 100, Baltimore, Maryland 21224, USA. 134 Center for Public Health Genomics, Department of Medicine
(Cardiovascular Medicine), University of Virginia, PO Box 800717, Charlottesville, Virginia 22908, USA. 135 Department of Clinical Physiology, Tampere
University Hospital, University of Tampere, School of Medicine, Tampere 33521, Finland. 136 University Institute of Social and Preventive Medicine, Centre
Hospitalier Universitaire Vaudois, University of Lausanne, Route de la Corniche 2, Epalinges CH-1066, Switzerland. 137 INSERM UMR970, Paris Cardiovascular
Research Center (PARCC), 56 rue Leblanc, Paris F-75015, France. 138 Paris Descartes University, Faculty of medicine, Paris Cite´ Sorbonne, 12 Rue de l’e´cole de
Me´decine, Paris F-75006, France. 139 Brigham and Women’s Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA.
140Wellcome Trust Sanger Institute, Hinxton CB10 1HH, UK. 141 University of Zurich, Institute of Physiology, Mechanisms of Inherited Kidney Disorders Group,
Winterthurerstrasse 190, Zu¨rich 8057, Switzerland. 142 Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku
University Hospital, Department of Clinical Physiology, PO Box 52, Turku 20521, Finland. 143 Department Clinical Pharmacology, William Harvey Research
Institute, Queen Mary University of London, London EC1M 6BQ, UK. 144NIHR Barts Cardiovascular Biomedical Research Unit, Queen Mary University of
London, London EC1M 6BQ, UK. 145Harvard Medical School, 900 Commonwealth Avenue East, Boston, Massachusetts 02115, USA. 146 University of
Alabama at Birmingham, Department of Medicine, 1530 3rd Avenue, South Birmingham, Alabama 35294-0022, USA. 147 University of Alabama at
Birmingham, Department of Epidemiology, 1530 3rd Avenue, South Birmingham, Alabama 35294-0022, USA. 148 Department of Psychiatry and EMGOþ
Institute, VU University Medical Center, A.J. Ernststraat 1187, Amsterdam 1081 HL, The Netherlands. 149 IFB AdiposityDiseases, University of Leipzig,
Liebigstrae 21, Leipzig 04103, Germany. 150Medical University Center Mainz, Langenbeckstrae 1, Mainz 55131, Germany. 151 Institute of Physiology,
University of Greifswald, Greifswald 17487, Germany. 152 Clinic for Prosthodontic Dentistry, Gerostomatology and Material Science, University of Greifswald,
Rotgerberstrae 8, Greifswald 17475, Germany. 153 School of Biomedical Sciences and Pharmacy, University of Newcastle, Hunter Medical Research Institute,
John Hunter Hospital, Locked Bag 1, HRMC, New South Wales 2310, Australia. 154 Kidney Research Institute, University of Washington, Box 359606, 325 9th
Avenue, Seattle, Washington 98104, USA. 155 Institute for Maternal and Child Health—IRCCS "Burlo Garofolo", Via dell’Istria 65, Trieste 34137, Italy.
156 Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.
157 Clinic for Internal Medicine A, University of Greifswald, Friedrich-Loefﬂer-Strae 23a, Greifswald 17475, Germany. 158 Faculty of Pharmaceutical Sciences,
University of Iceland, Sæmundargata 2, Reykjavik 101, Iceland. 159 Department of Clinical Physiology, Turku University Hospital, Research Centre of Applied
and Preventive Cardiovascular Medicine, University of Turku, PO Box 52, Turku 20521, Finland. 160 Synlab Academy, Synlab Services GmbH, Oberer Eselsberg
45, Ulm 89081, Germany. 161 Department of Internal Medicine II—Cardiology, University of Ulm Medical Centre, Albert-Einstein-Allee 23, Ulm 89081,
Germany. 162 The Mindich Child Health and Development Institute, Ichan School of Medicine at Mount Sinai, New York, New York 10029, USA.
163 Department of Neurology, General Central Hospital, Via Lorenz Bohler 5, Bolzano 39100, Italy. 164 Department of Neurology, University of Lu¨beck,
Ratzeburger Allee 160, Lu¨beck 23538, Germany. 165 University of Maryland Medical School, Division of Nephrology, 685 W. Baltimore Street, MSTF 314,
Baltimore, Maryland 21201, USA. 166 CRCHUM, University of Montreal, CHUM Research Center, Technopoˆle Angus, 900 Saint-Denis, Montreal, Que´bec,
Canada H2X 0A9. 167 Division of Endocrinology, Brigham and Women s Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, Massachusetts
02115, USA. * These authors contributed equally to this work. ** These authors jointly supervised this work. wA full list of consortium members appears at the
end of the paper.
zDeceased.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10023
14 NATURE COMMUNICATIONS | 7:10023 | DOI: 10.1038/ncomms10023 | www.nature.com/naturecommunications
ICBP Consortium
Goncalo R. Abecasis168, Linda S. Adair169, Myriam Alexander170, David Altshuler171,172, Najaf Amin24,
Dan E. Arking173, Pankaj Arora174, Yurii Aulchenko24, Stephan J.L. Bakker76, Stefania Bandinelli175,
Ines Barroso140, Jacques S. Beckmann176, John P. Beilby177, Richard N. Bergman178, Sven Bergmann176,
Joshua C. Bis179, Michael Boehnke168, Lori L. Bonnycastle180, Stefan R. Bornstein181, Michiel L. Bots182,
Jennifer L. Bragg-Gresham168, Stefan-Martin Brand183, Eva Brand184, Peter S. Braund185, Morris J. Brown186,
Paul R. Burton187, Juan P. Casas188, Mark J. Caulﬁeld189, Aravinda Chakravarti173, John C. Chambers190,
Giriraj R. Chandak191, Yen-Pei C. Chang192, Fadi J. Charchar193, Nish Chaturvedi194, Yoon Shin Cho195,
Robert Clarke196, Francis S. Collins180, Rory Collins196, John M. Connell197, Jackie A. Cooper198,
Matthew N. Cooper199, Richard S. Cooper200, Anna Maria Corsi201, Marcus Do¨rr202, Santosh Dahgam203,
John Danesh170, George Davey Smith204, Ian N.M. Day204, Panos Deloukas140, Matthew Denniff185,
Anna F. Dominiczak205, Yanbin Dong206, Ayo Doumatey26, Paul Elliott190, Roberto Elosua207,
Jeanette Erdmann208, Susana Eyheramendy209, Martin Farrall210, Cristiano Fava211, Terrence Forrester212,
F. Gerald R. Fowkes87, Ervin R. Fox213, Timothy M. Frayling214, Pilar Galan215, Santhi K. Ganesh216,
Melissa Garcia217, Tom R. Gaunt204, Nicole L. Glazer179, Min Jin Go195, Anuj Goel210, Ju¨rgen Gra¨ssler181,
Diederick E. Grobbee182, Leif Groop218, Simonetta Guarrera219, Xiuqing Guo220, David Hadley221,
Anders Hamsten222, Bok-Ghee Han195, Rebecca Hardy223, Anna-Liisa Hartikainen224, Simon Heath225,
Susan R. Heckbert226, Bo Hedblad211, Serge Hercberg215, Dena Hernandez20, Andrew A. Hicks1, Gina Hilton173,
Aroon D. Hingorani227, Judith A. Hoffman Bolton7, Jemma C. Hopewell196, Philip Howard228,
Steve E. Humphries198, Steven C. Hunt229, Kristian Hveem230, M. Arfan Ikram24, Muhammad Islam231,232,
Naoharu Iwai233,234, Marjo-Riitta Jarvelin190, Anne U. Jackson168, Tazeen H. Jafar231,232, Charles S. Janipalli191,
Toby Johnson189, Sekar Kathiresan235, Kay-Tee Khaw170, Hyung-Lae Kim195, Sanjay Kinra236, Yoshikuni Kita237,
Mika Kivimaki227, Jaspal S. Kooner238, M.J. Kranthi Kumar191, Diana Kuh223, Smita R. Kulkarni239,
Meena Kumari240, Johanna Kuusisto241, Tatiana Kuznetsova242, Markku Laakso241, Maris Laan243,
Jaana Laitinen244, Edward G. Lakatta245, Carl D. Langefeld246, Martin G. Larson247, Mark Lathrop225,
Debbie A. Lawlor204, Robert W. Lawrence199, Jong-Young Lee195, Nanette R. Lee248, Daniel Levy247, Yali Li249,
Will T. Longstreth250, Jian’an Luan251, Gavin Lucas207, Barbara Ludwig181, Massimo Mangino252,
K. Radha Mani191, Michael G. Marmot227, Francesco U.S. Mattace-Raso24, Giuseppe Matullo253,
Wendy L. McArdle254, Colin A. McKenzie212, Thomas Meitinger255, Olle Melander211, Pierre Meneton256,
James F. Meschia257, Tetsuro Miki258,259, Yuri Milaneschi124, Karen L. Mohlke260, Vincent Mooser261,
Mario A. Morken180, Richard W. Morris262, Thomas H. Mosley263, Samer Najjar264, Narisu Narisu180,
Christopher Newton-Cheh174, Khanh-Dung Hoang Nguyen173, Peter Nilsson211, Fredrik Nyberg203,
Christopher J. O’Donnell247, Toshio Ogihara265, Takayoshi Ohkubo266, Tomonori Okamura233,234,
Rick Twee-Hee Ong267, Halit Ongen210, N. Charlotte Onland-Moret182, Paul F. O’Reilly190, Elin Org243,
Marco Orru268, Walter Palmas269, Jutta Palmen198, Lyle J. Palmer199, Nicholette D. Palmer246, Alex N. Parker270,
John F. Peden210, Leena Peltonen140, Markus Perola271, Vasyl Pihur173, Carl G.P. Platou230, Andrew Plump272,
Dorairajan Prabhakaran273, Bruce M. Psaty179, Leslie J. Raffel220, Dabeeru C. Rao274, Asif Rasheed275,
Fulvio Ricceri253, Kenneth M. Rice276, Annika Rosengren277, Jerome I. Rotter220, Megan E. Rudock278,
Siim So˜ber243, Tunde Salako279, Danish Saleheen275, Veikko Salomaa271, Nilesh J. Samani185,
Steven M. Schwartz226, Peter E.H. Schwarz280, Laura J. Scott168, James Scott238, Angelo Scuteri245,
Joban S. Sehmi238, Mark Seielstad281, Sudha Seshadri14, Pankaj Sharma282, Sue Shaw-Hawkins189, Gang
Shi274, Nick R.G. Shrine187, Eric J.G. Sijbrands24, Xueling Sim283, Andrew Singleton20, Marketa Sjo¨gren211,
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10023 ARTICLE
NATURE COMMUNICATIONS | 7:10023 | DOI: 10.1038/ncomms10023 | www.nature.com/naturecommunications 15
Nicholas L. Smith226, Maria Soler Artigas187, Tim D. Spector252, Jan A. Staessen244, Alena Stancakova241,
Nanette I. Steinle192, David P. Strachan221, Heather M. Stringham168, Yan V. Sun106, Amy J. Swift180,
Yasuharu Tabara258,259, E-Shyong Tai284, Philippa J. Talmud198, Andrew Taylor240, Janos Terzic285, Dag S.
Thelle286, Martin D. Tobin189, Maciej Tomaszewski185, Vikal Tripathy273, Jaakko Tuomilehto287,
Ioanna Tzoulaki190, Manuela Uda268, Hirotsugu Ueshima288, Cuno S.P.M. Uiterwaal184, Satoshi Umemura289,
Pim van der Harst93, Yvonne T. van der Schouw182, Wiek H. van Gilst93, Erkki Vartiainen271, Ramachandran S.
Vasan247, Gudrun Veldre243, Germaine C. Verwoert24, Margus Viigimaa290, D.G. Vinay191, Paolo Vineis291,
Benjamin F. Voight235, Peter Vollenweider292, Lynne E. Wagenknecht246, Louise V. Wain187, Xiaoling Wang206,
Thomas J. Wang247, Nicholas J. Wareham251, Hugh Watkins210, Alan B. Weder216, Peter H. Whincup221,
Kerri L. Wiggins179, Jacqueline C.M. Witteman24, Andrew Wong223, Ying Wu259, Chittaranjan S. Yajnik239,
Jie Yao220, J.H. Young293, Diana Zelenika225, Guangju Zhai252, Weihua Zhang190, Feng Zhang252,
Jing Hua Zhao251, Haidong Zhu206, Xiaofeng Zhu249, Paavo Zitting294, Ewa Zukowska-Szczechowska295
168Center for Statistical Genetics, Department of Biostatistics, University of Michigan, School of Public Health, Ann Arbor, Michigan 48103, USA.
169Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina 27599, USA. 170Department of Public Health and Primary Care,
University of Cambridge, Cambridge, CB1 8RN, UK. 171Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA. 172Department
of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA. 173Center for Complex Disease Genomics, McKusick-Nathans Institute of Genetic
Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA. 174Center for Human Genetic Research, Cardiovascular Research
Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. 175Geriatric Rehabilitation Unit, Azienda Sanitaria Firenze (ASF), 50125
Florence, Italy. 176De´partement de Ge´ne´tique Me´dicale, Universite´ de Lausanne, Lausanne 1015, Switzerland. 177Pathology and Laboratory Medicine,
University of Western Australia, 6009 Crawley, Western Australia, Australia. 178Department of Physiology and Biophysics, Keck School of Medicine,
University of Southern California, Los Angeles, California 90033, USA. 179Cardiovascular Health Research Unit, Department of Medicine, University of
Washington, Seattle 98195, Washington, USA. 180National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892,
USA. 181Department of Medicine III, Medical Faculty Carl Gustav Carus at the Technical University of Dresden, Dresden 01307, Germany. 182Julius Center for
Health Sciences and Primary Care, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3508 GA, The Netherlands. 183Leibniz-Institute for
Arteriosclerosis Research, Department of Molecular Genetics of Cardiovascular Disease, University of Mu¨nster, Mu¨nster, Germany. 184University Hospital
Mu¨nster, Internal Medicine D, Mu¨nster, Germany. 185Department of Cardiovascular Sciences, University of Leicester, Glenﬁeld Hospital, Leicester LE3 9QP,
UK. 186Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Hills Road, Cambridge CB2 2QQ, UK. 187Department of Health
Sciences, University of Leicester, University Rd, Leicester LE1 7RH, UK. 188Faculty of Epidemiology and Population Health, London School of Hygiene and
Tropical Medicine, London WC1E 7HT, UK. 189Clinical Pharmacology and The Genome Centre, William Harvey Research Institute, Barts and The London
School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK. 190Department of Epidemiology and Biostatistics, School of
Public Health, Imperial College London, Norfolk Place, London W2 1PG, UK. 191Centre for Cellular and Molecular Biology (CCMB), Council of Scientiﬁc and
Industrial Research (CSIR), Uppal Road, Hyderabad 500 007, India. 192University of Maryland, School of Medicine, Baltimore, Maryland 21201, USA.
193School of Science and Engineering, University of Ballarat, Ballarat 3353, Australia. 194International Centre for Circulatory Health, National Heart & Lung
Institute, Imperial College, London, UK. 195Center for Genome Science, National Institute of Health, Seoul, Korea. 196Clinical Trial Service Unit and
Epidemiological Studies Unit, University of Oxford, Oxford OX3 7LF, UK. 197University of Dundee, Ninewells Hospital & Medical School, Dundee DD1 9SY, UK.
198Centre for Cardiovascular Genetics, University College London, London WC1E 6JF, UK. 199Centre for Genetic Epidemiology and Biostatistics, University of
Western Australia, Crawley, Western Australia, Australia. 200Department of Preventive Medicine and Epidemiology, Loyola University Medical School,
Maywood, Illinois, USA. 201Tuscany Regional Health Agency, Florence, Italy. 202Department of Internal Medicine B, Ernst-Moritz-Arndt-University Greifswald,
Greifswald 17487, Germany. 203Occupational and Environmental Medicine, Department of Public Health and Community Medicine, Institute of Medicine,
Sahlgrenska Academy, University of Gothenburg, Gothenburg 40530, Sweden. 204MRC Centre for Causal Analyses in Translational Epidemiology, School of
Social & Community Medicine, University of Bristol, Bristol BS8 2BN, UK. 205BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126
University Place, Glasgow G12 8TA, UK. 206Georgia Prevention Institute, Department of Pediatrics, Medical College of Georgia, 30912 Augusta, Georgia,
USA. 207Cardiovascular Epidemiology and Genetics, Institut Municipal d’Investigacio Medica, Barcelona Biomedical Research Park, 88 Doctor Aiguader,
Barcelona 08003, Spain. 208Medizinische Klinik II, Universita¨t zu Lu¨beck, 23562 Lu¨beck, Germany. 209Department of Statistics, Pontiﬁcia Universidad
Catolica de Chile, Vicun˜a Mackena, Santiago 4860, Chile. 210Department of Cardiovascular Medicine, The Wellcome Trust Centre for Human Genetics,
University of Oxford, Oxford OX3 7BN, UK. 211Department of Clinical Sciences, Lund University, SE-205 02 Malmo¨, Sweden. 212Tropical Medicine Research
Institute, University of the West Indies, Mona, Kingston, Jamaica. 213Department of Medicine, University of Mississippi Medical Center, 2500 North State St,
Jackson, Mississippi 39216, USA. 214Genetics of Complex Traits, Peninsula Medical School, University of Exeter, EX1 2LU Exeter, UK. 215U557 Institut National
de la Sante´ et de la Recherche Me´dicale, U1125 Institut National de la Recherche Agronomique, Universite´ Paris 13, F-93017 Bobigny, France. 216Department
of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical Center, Ann Arbor 48108, Michigan, USA. 217Laboratory of
Epidemiology, Demography, Biometry, National Institute on Aging, National Institutes of Health, Bethesda, Maryland 20892, USA. 218Department of Clinical
Sciences, Diabetes and Endocrinology Research Unit, University Hospital, SE-205 02 Malmo¨, Sweden. 219Human Genetics Foundation (HUGEF), Via
Lagrange 35, Torino 10123, Italy. 220Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, 90048 California, USA. 221Division of Community
Health Sciences, St George’s University of London, London SW17 0RE, UK. 222Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute,
SE-171 77 Stockholm, Sweden. 223MRC Unit for Lifelong Health & Ageing, London WC1B 5JU, UK. 224Institute of Clinical Medicine/Obstetrics and
Gynecology, University of Oulu, 90014 Oulu, Finland. 225Centre National de Ge´notypage, Commissariat de L’Energie Atomique, Institut de Ge´nomique,
91000 Evry, France. 226Department of Epidemiology, University of Washington, Seattle, Washington 98195, USA. 227Epidemiology Public Health, UCL,
London WC1E 6BT, UK. 228William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London,
London EC1M 6BQ, UK. 229Cardiovascular Genetics, University of Utah, School of Medicine, Salt Lake City, 84132 Utah, USA. 230HUNT Research Centre,
Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger 7600, Norway. 231Department of Community
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10023
16 NATURE COMMUNICATIONS | 7:10023 | DOI: 10.1038/ncomms10023 | www.nature.com/naturecommunications
Health Sciences, Aga Khan University, 74800 Karachi, Pakistan. 232Department of Medicine, Aga Khan University, 74800 Karachi, Pakistan. 233Department
of Genomic Medicine, National Cerebral and Cardiovascular Research Center, Suita 565-8565, Japan. 234Department of Preventive Cardiology, National
Cerebral and Cardiovascular Research Center, Suita 565-8565, Japan. 235Medical Population Genetics, Broad Institute of Harvard and MIT, 5 Cambridge
Center, Cambridge, Massachusetts 02142, USA. 236Division of Non-communicable disease Epidemiology, The London School of Hygiene and Tropical
Medicine London, Keppel Street, London WC1E 7HT, UK. 237Department of Health Science, Shiga University of Medical Science, Otsu 520-2192, Japan.
238National Heart and Lung Institute, Imperial College London, London W12 0HS, UK. 239Diabetes Unit, KEM Hospital and Research Centre, Rasta Peth, Pune,
411011 Maharashtra, India. 240Genetic Epidemiology Group, Epidemiology and Public Health, UCL, London WC1E 6BT, UK. 241Department of Medicine,
University of Kuopio, Kuopio University Hospital, Kuopio 70210, Finland. 242Studies Coordinating Centre, Division of Hypertension and Cardiac Rehabilitation,
Department of Cardiovascular Diseases, University of Leuven, Campus Sint Rafae¨l, Kapucijnenvoer 35, Block D, Box 7001, Leuven 3000, Belgium. 243Institute
of Molecular and Cell Biology, University of Tartu, Riia 23, Tartu 51010, Estonia. 244Finnish Institute of Occupational Health, Finnish Institute of Occupational
Health, Aapistie 1, Oulu 90220, Finland. 245Gerontology Research Center, National Institute on Aging, Baltimore, Maryland 21224, USA. 246Wake Forest
University Health Sciences, Winston-Salem, North Carolina 27157, USA. 247National Heart, Lung and Blood Institute Framingham Heart Study, Framingham,
01702-5827 Massachusetts, USA. 248Ofﬁce of Population Studies Foundation, University of San Carlos, Talamban, Cebu 6000, Philippines. 249Department
of Epidemiology and Biostatistics, Case Western Reserve University, 2103 Cornell Road, Cleveland, Ohio 44106, USA. 250Department of Medicine and
Neurology, University of Washington, Seattle, Washington 98195, USA. 251MRC Epidemiology Unit, Institute of Metabolic Science, Cambridge CB2 0QQ, UK.
252Department of Twin Research and Genetic Epidemiology, King’s College London, SE1 7EH London, UK. 253Department of Genetics, Biology and
Biochemistry, University of Torino, Via Santena 19, Torino 10126, Italy. 254ALSPAC Laboratory, University of Bristol, Bristol BS8 2BN, UK. 255Institute of Human
Genetics, Helmholtz Zentrum Munich, German Research Centre for Environmental Health, Neuherberg 85764, Germany. 256U872 Institut National de la
Sante´ et de la Recherche Me´dicale, Centre de Recherche des Cordeliers, 75006 Paris, France. 257Mayo Clinic, Jacksonville, 32224 Florida, USA.
258Department of Basic Medical Research and Education, Ehime University Graduate School of Medicine, Toon 791-0295, Japan. 259Department of Geriatric
Medicine, Ehime University Graduate School of Medicine, Toon 791-0295, Japan. 260Department of Genetics, University of North Carolina, Chapel Hill, North
Carolina 27599, USA. 261Division of Genetics, GlaxoSmithKline, Philadelphia, Pennsylvania 19101, USA. 262Department of Primary Care and Population
Health, UCL, London NW3 2PF, UK. 263Department of Medicine (Geriatrics), University of Mississippi Medical Center, Jackson, 39216 Mississippi, USA.
264Laboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging, NIH, Baltimore, 21224-6825 Maryland, USA.
265Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, Japan. 266Tohoku University, Graduate School of
Pharmaceutical Sciences and Medicine, Sendai 980-8578, Japan. 267Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore
138672, Singapore. 268Istituto di Neurogenetica e Neurofarmacologia, Consiglio Nazionale delle Ricerche, Cittadella Universitaria di Monserrato, 09042
Monserrato, Cagliari, Italy. 269Columbia University, New York, 10027 New York, USA. 270Amgen, 1 Kendall Square, Building 100, Cambridge, Massachusetts
02139, USA. 271National Institute for Health and Welfare, Helsinki 00271, Finland. 272Merck Research Laboratory, 126 East Lincoln Avenue, Rahway, New
Jersey 07065, USA. 273South Asia Network for Chronic Disease, Public Health Foundation of India, C-1/52, SDA, New Delhi 100016, India. 274Division of
Biostatistics, Washington University School of Medicine, Saint Louis, Missouri 63110, USA. 275Center for Non-Communicable Diseases, 74800 Karachi,
Pakistan. 276Department of Biostatistics, University of Washington, Seattle, 98105 Washington, USA. 277Department of Emergency and Cardiovascular
Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg 41685, Sweden. 278Epidemiology & Prevention, Division of
Public Health Sciences, Wake Forest University, School of Medicine, Winston-Salem, North Carolina 27157, USA. 279University of Ibadan, PMB 5017 Ibadan,
Nigeria. 280Prevention and Care of Diabetes, Department of Medicine III, Medical Faculty Carl Gustav Carus at the Technical University of Dresden, Dresden
01307, Germany. 281Department of Laboratory Medicine, Institute of Human Genetics, University of California, San Francisco, 513 Parnassus Avenue, San
Francisco, California 94143, USA. 282Imperial College Cerebrovascular Unit (ICCRU), Imperial College, London W6 8RF, UK. 283Centre for Molecular
Epidemiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore. 284Department of Medicine, Yong Loo Lin
School of Medicine, National University of Singapore, Singapore 119074, Singapore. 285Faculty of Medicine, University of Split, 21000 Split, Croatia.
286Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo 0317, Norway. 287Diabetes Prevention Unit, National Institute for
Health and Welfare, Helsinki 00271, Finland. 288Lifestyle-related Disease Prevention Center, Shiga University of Medical Science, Otsu 520-2192, Japan.
289Department of Medical Science and Cardiorenal Medicine, Yokohama City University School of Medicine, Yokohama 236-0004, Japan. 290Tallinn
University of Technology, Institute of Biomedical Engineering, Ehitajate tee 5, Tallinn 19086, Estonia. 291Department of Epidemiology and Public Health,
Imperial College, Norfolk Place, London W2 1PG, UK. 292Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne 1011,
Switzerland. 293Department of Medicine, Johns Hopkins University, Baltimore, 21205 Maryland, USA. 294Lapland Central Hospital, Department of
Physiatrics, Box 8041, Rovaniemi 96101, Finland. 295Department of Internal Medicine, Diabetology, and Nephrology, Medical University of Silesia,
Zabrze 41-800, Poland.
AGEN Consortium
Yukinori Okada296,297, Jer-Yuarn Wu298,299, Dongfeng Gu300, Fumihiko Takeuchi301, Atsushi Takahashi296, Shiro
Maeda302, Tatsuhiko Tsunoda303, Peng Chen304, Su-Chi Lim305,306, Tien-Yin Wong307,308,309, Jianjun Liu267,
Terri L. Young310, Tin Aung307,308, Yik-Ying Teo267,283,306,311,312, Young Jin Kim313, Daehee Kang314, Chien-Hsiun
Chen298,299, Fuu-Jen Tsai299, Li-Ching Chang298, S.-J. Cathy Fann298, Hao Mei315, James E. Hixson34, Shufeng
Chen300, Tomohiro Katsuya316,317, Masato Isono301, Eva Albrecht66, Kazuhiko Yamamoto318, Michiaki Kubo319,
Yusuke Nakamura320, Naoyuki Kamatani321, Norihiro Kato301, Jiang He315, Yuan-Tsong Chen298, Toshihiro
Tanaka297,322
296Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa 230-0045, Japan. 297Department of Human
Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan. 298Institute of
Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan. 299School of Chinese Medicine, China Medical University, Taichung 404, Taiwan. 300Cardiovascular
Institute and Fu Wai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100037, China. 301Department of Gene
Diagnostics and Therapeutics, Research Institute, National Center for Global Health and Medicine, Tokyo 162-8655, Japan. 302Laboratory for Endocrinology
and Metabolism, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa 230-0045, Japan. 303Laboratory for Medical Informatics, RIKEN
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10023 ARTICLE
NATURE COMMUNICATIONS | 7:10023 | DOI: 10.1038/ncomms10023 | www.nature.com/naturecommunications 17
Center for Integrative Medical Sciences, Yokohama, Kanagawa 230-0045, Japan. 304Saw Swee Hock School of Public Health, National University of
Singapore, Singapore 119077, Singapore. 305Department of Medicine, Khoo Teck Puat Hospital, Singapore 768828, Singapore. 306Department of
Epidemiology and Public Health, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore. 307Singapore Eye Research
Institute, Singapore National Eye Centre, Singapore 168751, Singapore. 308Department of Ophthalmology, Yong Loo Lin School of Medicine, National
University of Singapore, Singapore 117597, Singapore. 309Centre for Eye Research Australia, University of Melbourne, East Melbourne, 3002 Victoria,
Australia. 310Center for Human Genetics, Duke University Medical Center, Durham, 27710 North Carolina, USA. 311Department of Statistics and Applied
Probability, National University of Singapore, Singapore 117546, Singapore. 312NUS Graduate School for Integrative Science and Engineering, National
University of Singapore, Singapore 119077, Singapore. 313Center for Genome Science, National Institute of Health, Osong Health Technology Administration
Complex, 187 Chungcheongbuk-do, Korea. 314Department of Preventive Medicine, Seoul National University College of Medicine, Seoul 08826, Korea.
315Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, 70112 Louisiana, USA. 316Department of
Clinical Gene Therapy, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan. 317Department of Geriatric Medicine and Nephrology,
Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan. 318Department of Allergy and Rheumatology, Graduate School of Medicine,
University of Tokyo, Tokyo 113-0033, Japan. 319Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama,
Kanagawa 230-0045, Japan. 320Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo 108-
8639, Japan. 321Laboratory for International Alliance, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa 230-0045, Japan. 322Laboratory
for Cardiovascular Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa 230-0045, Japan.
CARDIOGRAM
Muredach P. Reilly323, Heribert Schunkert57,324,325, Themistocles L. Assimes326, Alistair Hall327, Christian
Hengstenberg328, Inke R. Ko¨nig329, Reijo Laaksonen330, Ruth McPherson331, John R. Thompson187, Unnur
Thorsteinsdottir332,333, Andreas Ziegler329, Devin Absher334, Li Chen335, L. Adrienne Cupples13,247, Eran
Halperin336,337, Mingyao Li338, Kiran Musunuru140,339,340, Michael Preuss324,329, Arne Schillert329, Gudmar
Thorleifsson332, George A. Wells335, Hilma Holm332, Robert Roberts331, Alexandre F.R. Stewart331, Stephen
Fortmann326, Alan Go341, Mark Hlatky326, Carlos Iribarren341, Joshua Knowles326, Richard Myers334, Thomas
Quertermous326, Steven Sidney341, Neil Risch342, Hua Tang343, Stefan Blankenberg344, Renate Schnabel344,
Christoph Sinning344, Karl J. Lackner345, Laurence Tiret346, Viviane Nicaud346, Francois Cambien346,
Christoph Bickel344, Hans J. Rupprecht344, Claire Perret346, Carole Proust346, Thomas F. Mu¨nzel344, Maja
Barbalic34, Ida Yii-Der Chen220, Serkalem Demissie-Banjaw246,347, Aaron Folsom348, Thomas Lumley275, Kristin
Marciante349, Kent D. Taylor220, Kelly Volcik350, Solveig Gretarsdottir332, Jeffrey R. Gulcher332, Augustine
Kong332, Kari Stefansson332,333, Gudmundur Thorgeirsson333,351, Karl Andersen333,351, Marcus Fischer328, Anika
Grosshennig324,329, Patrick Linsel-Nitschke324, Klaus Stark328, Stefan Schreiber38, Zouhair Aherrahrou57,324,
Petra Bruse57,324, Angela Doering352, Norman Klopp352, Patrick Diemert324, Christina Loley324,329, Anja
Medack57,324, Janja Nahrstedt324,329, Annette Peters68, Arnika K. Wagner324, Christina Willenborg57,324,
Bernhard O. Bo¨hm353, Harald Dobnig354, Tanja B. Grammer355, Michael M. Hoffmann356, Andreas Meinitzer357,
Bernhard R. Winkelmann358, Stefan Pilz354, Wilfried Renner357, Hubert Scharnagl357, Tatjana Stojakovic357,
Andreas Tomaschitz354, Karl Winkler356, Candace Guiducci16, Noel Burtt16, Stacey B. Gabriel16, Sonny
Dandona331, Olga Jarinova331, Liming Qu338, Robert Wilensky323, William Matthai323, Hakon H. Hakonarson359,
Joe Devaney360, Mary Susan Burnett360, Augusto D. Pichard360, Kenneth M. Kent360, Lowell Satler360, Joseph
M. Lindsay360, Ron Waksman360, Christopher W. Knouff361, Dawn M. Waterworth361, Max C. Walker361,
Stephen E. Epstein360, Daniel J. Rader323,362, Christopher P. Nelson185, Benjamin J. Wright363, Anthony J.
Balmforth364, Stephen G. Ball365
323The Cardiovascular Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. 324Institut fu¨r integrative und experimentelle Genomik,
Universita¨t zu Lu¨beck, Lu¨beck 23562, Germany. 325Deutsches Herzzentrum Mu¨nchen, Technische Universita¨t Mu¨nchen, Mu¨nchen 80636, Germany.
326Department of Medicine, Stanford University School of Medicine, Stanford, 94305-5101 California, USA. 327Division of Cardiovascular and Neuronal
Remodelling, Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds LS2 9JT, UK.
328Klinik und Poliklinik fu¨r Innere Medizin II, Universita¨t Regensburg, 93053 Regensburg, Germany. 329Institut fu¨r Medizinische Biometrie und Statistik,
Universita¨t zu Lu¨beck, 23562 Lu¨beck, Germany. 330Science Center, Tampere University Hospital, Tampere 33521, Finland. 331The John & Jennifer Ruddy
Canadian Cardiovascular Genetics Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada K1Y 4W7. 332deCODE Genetics, Reykjavik 101,
Iceland. 333Faculty of Medicine, University of Iceland, Reykjavik 101, Iceland. 334Hudson Alpha Institute, Huntsville, 35806 Alabama, USA. 335Cardiovascular
Research Methods Centre, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario, Canada K1Y 4W7. 336The Blavatnik School of Computer
Science, Department of Molecular Microbiology and Biotechnology, Tel-Aviv University, Tel-Aviv 6997801, Israel. 337The International Computer Science
Institute, Berkeley, 94704 California, USA. 338Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, 19104 Pennsylvania, USA.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10023
18 NATURE COMMUNICATIONS | 7:10023 | DOI: 10.1038/ncomms10023 | www.nature.com/naturecommunications
339Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital, Boston, 02114 Massachusetts, USA. 340Center for Human
Genetic Research, Massachusetts General Hospital, Boston, 02114 Massachusetts, USA. 341Division of Research, Kaiser Permanente, Oakland, 94611
California, USA. 342Institute for Human Genetics, University of California, San Francisco, San Francisco, 94143 California, USA. 343Department of
Cardiovascular Medicine, Cleveland Clinic 7255 Old Oak Blvd, Cleveland, Ohio 44130, USA. 344Medizinische Klinik und Poliklinik, Johannes-Gutenberg
Universita¨t Mainz, Universita¨tsmedizin, 55122 Mainz, Germany. 345Institut fu¨r Klinische Chemie und Laboratoriumsmediizin, Johannes-Gutenberg Universita¨t
Mainz, Universita¨tsmedizin, 55122 Mainz, Germany. 346INSERM UMRS 937, Pierre and Marie Curie University (UPMC, Paris 6) and Medical School, 75005
Paris, France. 347Boston University, School of Public Health, Boston, 02118 Massachusetts, USA. 348University of Minnesota School of Public Health, Division
of Epidemiology and Community Health, School of Public Health (A.R.F.), Minneapolis, 55454 Minnesota, USA. 349University of Washington, Department of
Internal Medicine, Seattle, 98195-6420 Washington, USA. 350University of Texas, School of Public Health, Houston, 77030 Texas, USA. 351Department of
Medicine, Landspitali University Hospital, Reykjavik 101, Iceland. 352Institute of Epidemiology, Helmholtz Zentrum Mu¨nchen, German Research Center for
Environmental Health, 85764 Neuherberg, Germany. 353Division of Endocrinology and Diabetes, Graduate School of Molecular Endocrinology and Diabetes,
University of Ulm, 89069 Ulm, Germany. 354Division of Endocrinology, Department of Medicine, Medical University of Graz, 8010 Graz, Austria. 355Synlab
Center of Laboratory Diagnostics Heidelberg, 69037 Heidelberg, Germany. 356Division of Clinical Chemistry, Department of Medicine, Albert Ludwigs
University, 79085 Freiburg, Germany. 357Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz, 8010 Graz, Austria.
358Cardiology Group Frankfurt-Sachsenhausen, 60594 Frankfurt, Germany. 359The Center for Applied Genomics, Children’s Hospital of Philadelphia, 19104
Philadelphia, Pennsylvania, USA. 360Cardiovascular Research Institute, Medstar Health Research Institute, Washington Hospital Center, Washington, DC
20010, USA. 361Genetics Division and Drug Discovery, GlaxoSmithKline, King of Prussia, Pennsylvania 19406, USA. 362The Institute for Translational
Medicine and Therapeutics, School of Medicine, University of Pennsylvania, Philadelphia, 19104-5158 Pennsylvania, USA. 363Department of Cardiovascular
Surgery, University of Leicester, Leicester LE1 7RH, UK. 364Division of Cardiovascular and Diabetes Research, Multidisciplinary Cardiovascular Research
Centre, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds LS2 9JT, UK. 365LIGHT Research Institute, Faculty of Medicine and
Health, University of Leeds, Leeds LS2 9JT, UK.
CHARGe-Heart Failure Group
Laura R. Loehr366,367,368, Wayne D. Rosamond367, Emelia Benjamin247, Talin Haritunians220, David Couper369,
Joanne Murabito247, Ying A. Wang13, Bruno H. Stricker24, Patricia P. Chang366, James T. Willerson370,371
366Department of Medicine, University of North Carolina at Chapel Hill, North Carolina 27516, USA. 367Department of Epidemiology, University of North
Carolina at Chapel Hill, North Carolina 27599-7435, USA. 368National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina
27709, USA. 369Department of Biostatistics, University of North Carolina at Chapel Hill, North Carolina 27514, USA. 370University of Texas, Houston Health
Science Center, Houston, Texas 77030, USA. 371Texas Heart Institute, Houston, Texas 77225-0345, USA.
ECHOGen Consortium
Stephan B. Felix202, Norbert Watzinger372, Jayashri Aragam247, Robert Zweiker372, Lars Lind373, Richard J.
Rodeheffer374, Karin Halina Greiser375, Jaap W. Deckers376, Jan Stritzke377, Erik Ingelsson378, Iftikhar Kullo374,
Johannes Haerting375, Thorsten Reffelmann202, Margaret M. Redﬁeld374, Karl Werdan379, Gary F. Mitchell247,
Donna K. Arnett380, John S. Gottdiener381, Maria Blettner382, Nele Friedrich383
372Department of Internal Medicine, Division of Cardiology, Medical University Graz, Graz 8036, Austria. 373Department of Medical Sciences, Uppsala
University, Uppsala 75185, Sweden. 374Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA. 375Institute of Medical
Epidemiology, Biostatistics and Informatics, Martin Luther University of Halle-Wittenberg, Halle-Wittenberg, Halle (Saale) 06097, Germany. 376Department
of Cardiology, Erasmus University Medical Center, Rotterdam 3000 CA, The Netherlands. 377Medical Clinic 2, University of Lu¨beck, Lu¨beck 23538, Germany.
378Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm 17177, Sweden. 379Martin Luther University, Halle-Wittenberg,
Halle (Saale) 06097, Germany. 380Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama 35294-0022, USA.
381Division of Cardiology, University of Maryland Hospital, Baltimore, Maryland 21201, USA. 382Institute of Medical Biometry, Epidemiology, and Informatics,
Johannes Gutenberg University, Mainz 55101, Germany. 383Institute for Community Medicine, Ernst-Moritz-Arndt-Universita¨t, Greifswald 17475, Germany.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10023 ARTICLE
NATURE COMMUNICATIONS | 7:10023 | DOI: 10.1038/ncomms10023 | www.nature.com/naturecommunications 19
